Podcasts about National Health Service

Cybercrime's escalation has reached a projected $12.2 trillion annual impact by 2031, with a notable surge in remote monitoring and management (RMM) tool abuse—up 277% year-over-year, according to Huntress and supporting vendor reports. Attackers utilize legitimate IT tools to facilitate stealthier ransomware and phishing campaigns, amplifying structural vulnerabilities within MSP technology stacks. Key metrics from Acronis, WatchGuard, and Vectra AI indicate a shift to smaller, more evasive malware campaigns, longer times to ransomware deployment (averaging 20 hours), and widespread unaddressed security alerts, raising questions about the adequacy of current defenses and incident response practices. Vendor-supplied threat intelligence further shows that MSPs' reliance on signature-based platforms and insufficient visibility leaves them exposed to evolving attack techniques. Data reviewed suggests phishing footholds can quickly compromise cross-client environments, and legal ramifications heavily fall on the service provider when RMM or monitoring tools act as entry points. Notably, only about 58-60% of organizations report full visibility across their systems, with a majority of alerts remaining unaddressed, underscoring gaps in operational maturity and preparedness. Adjacent coverage highlighted Microsoft Copilot's repeated security control failures within regulated environments, specifically its inability to enforce sensitivity labels and boundaries across emails—most recently affecting the UK's National Health Service. The lack of vendor-announced architectural changes calls into question the viability of deploying AI tools in compliance-driven contexts. Separately, political and public backlash against surveillance technologies (such as Flock cameras) demonstrates that unchecked data collection is no longer a manageable passive risk, as data becomes increasingly actionable and retains liability beyond technical considerations. The practical takeaway for MSPs and IT leaders is a need to prioritize audit, documentation, and enforcement of controls within their technology stacks, especially where vendor tools or AI-driven automation intersect with compliance and client trust. Preserving operational optionality and scrutinizing vendor terms—particularly data sharing and architectural enforcement—are essential to reduce exposure. Waiting for vendor patches, disregarding documented control failures, or underestimating public scrutiny elevate liability across legal, reputational, and client relationship domains. Four things to know today: 00:00 Vendor Threat Reports Converge on One Risk MSPs Can't Outsource: The RMM as Breach Vector 05:11 Copilot Failed Compliance Controls Twice in Eight Months — A Patch Won't Fix That 07:03 Flock Backlash Exposes the Liability Hidden in Every Vendor Data-Sharing Contract 09:42 GTDC Summit: Distributors Pitch AI On-Ramp as Hyperscalers Compress Their Margin Sponsored by:  

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest on Ozempic from medical breakthroughs to real-life health impacts.Recent research from the University of Cambridge highlights a key nutrition risk with Ozempic and Wegovy. These drugs slash calorie intake by sixteen to thirty-nine percent by mimicking glucagon-like peptide-one, curbing appetite and boosting fullness. But without proper guidance, users risk muscle loss up to forty percent of total weight shed and deficiencies in protein, vitamins, and minerals, leading to fatigue, hair loss, or weakened immunity. Experts like Doctor Marie Spreckley urge structured nutrition support, drawing from bariatric surgery principles: prioritize nutrient-dense foods and high-quality protein spread across meals. Doctor Adrian Brown from University College London notes most users, about ninety-five percent in the United Kingdom, get these privately without follow-up, unlike National Health Service programs pairing them with diet and exercise.Sex differences are emerging too. A study in PubMed Central reports glucagon-like peptide-one receptor agonist use surged from twenty nineteen to twenty twenty-two, especially among women, where obesity links strongly to prescriptions and yields greater weight loss, like fifteen point three kilograms in semaglutide trials.Looking ahead per GoodRx projections for twenty twenty-six, Ozempic is under Food and Drug Administration review for peripheral artery disease, improving walking in diabetes patients, and heart failure with preserved ejection fraction. Higher Wegovy doses up to seven point two milligrams could hit nearly twenty-one percent weight loss. Exciting combos like CagriSema show twenty-three percent loss in trials, outpacing rivals. Oral options expand too: Wegovy pills launched this year, and orforglipron may approve mid-year, easing access without needles.The Food and Drug Administration warns against unapproved versions mimicking semaglutide, sold illegally online. Experts from George Mason University, like Martin Binks and Raedeh Basiri, stress holistic care: pair drugs with dietitians, exercise, and mental support to avoid regain, as a twenty twenty-six BMJ review notes two-thirds weight return within a year off meds.Ozempic transforms lives but thrives with lifestyle integration for lasting health.Thanks for tuning in, listeners. Subscribe for more updates. This has been a Quiet Please production. For more, check out Quiet Please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Is your teen's behavior a sign that something is “wrong”… or could it be part of normal development in a high-pressure world?When should parents seek help—and when might labels actually do more harm than good? In this powerful and thought-provoking episode, Colleen O'Grady sits down with child and adolescent psychiatrist Dr. Sami Timimi, author of Searching for Normal. With over 35 years in the UK's National Health Service, Dr. Timimi challenges many of the assumptions parents have been taught about teen mental health. Together, they explore why diagnoses like ADHD, autism, anxiety, and depression have exploded—and why medicalizing distress can sometimes steal hope instead of restoring it. This conversation reframes teen behavior through the lens of context, development, relationships, and resilience, reminding parents that emotions are not emergencies and that most teens are not broken—they're responding to a stressful world. About Dr. Sami Timimi Dr. Sami Timimi is a British child and adolescent psychiatrist with more than three decades of clinical experience in the UK's National Health Service. He has authored numerous academic papers and books and is widely known for his critiques of the over-medicalization of mental health. In Searching for Normal, Dr. Timimi offers a deeply humane, evidence-based challenge to psychiatric labeling and invites families to reclaim a more hopeful, relational understanding of distress. Three Takeaways for Parents Distress is not the same as disorder. Many teen struggles are understandable responses to pressure, change, and context—not signs of lifelong pathology. Labels shape identity—and not always in helpful ways. Diagnoses can unintentionally limit teens, increase fear, and turn temporary struggles into permanent stories. Relationships matter more than control. Teens don't need to be “fixed”—they need connection, patience, and adults who aren't afraid of emotions. Follow at: https://www.instagram.com/dr_samitimimi/?hl=en Learn More at: https://www.samitimimi.co.uk/ Learn more about your ad choices. Visit megaphone.fm/adchoices

FOLLOW RICHARD Website: https://www.strangeplanet.ca YouTube: @strangeplanetradio Instagram: @richardsyrettstrangeplanet TikTok: @therealstrangeplanet EP. #1313 Murdered by Protocol: COVID and the NHS Death Machine For years, we were told the greatest threat to humanity was a virus. But what if the real danger wasn't the pathogen—it was the protocol? Tonight on Strange Planet, Richard Syrett ventures into one of the darkest, least examined chapters of the COVID era. Drawing on firsthand testimony, medical records, and hard data, this episode investigates allegations that thousands of vulnerable patients in the UK's National Health Service may not have died from COVID, but because of policy-driven medical decisions. Sedation. Isolation. Denial of treatment—carried out under emergency authority and bureaucratic language. GUESTS: Jacqui Deevoy is an investigative journalist and filmmaker who spent decades writing for Britain's mainstream press before becoming persona non grata for asking forbidden questions. During the COVID era, she uncovered alarming patterns inside UK hospitals and care homes—blanket DNR orders, family exclusion, and the widespread use of end-of-life drugs on non-terminal patients. After the sudden death of her own father, Deevoy compiled testimonies from 42 families into Murdered by the State, a chilling civilian record of alleged involuntary euthanasia carried out under emergency powers. Richard Cox is an author, researcher, and host of The Deep State Consciousness Podcast. As co-editor of Murdered by the State, Cox provides the book's analytical backbone, examining excess mortality data, NHS protocols, drug procurement records, and historical precedents like the Liverpool Care Pathway. His work frames the COVID death surge not as medical chaos, but as systemic compliance—raising disturbing questions about how policy, not pathology, may have driven outcomes, and why those powers never fully disappeared. WEBSITES/LINKS: https://substack.com/@jacquideevoy https://www.deepstateconsciousness.com BOOK: Murdered by the State: Involuntary Euthanasia in Plain Sight SUPPORT OUR SPONSORS!!! QUINCE Luxury, European linen that gets softer with every wash! Turn up the luxury when you turn in with Quince. Go to Quince dot com slash RSSP for free shipping on your order and 365-day returns. Now available in Canada, too. BECOME A PREMIUM SUBSCRIBER!!!⁠ ⁠https://strangeplanet.supportingcast.fm⁠ Three monthly subscriptions to choose from. Commercial Free Listening, Bonus Episodes and a Subscription to my monthly newsletter, InnerSanctum. Visit ⁠https://strangeplanet.supportingcast.fm⁠ Use the discount code "Planet" to receive $5 OFF off any subscription. We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit ⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/

In this special episode, recorded live at the 2025 Genomics England Research Summit, host Adam Clatworthy is joined by parents, clinicians and researchers to explore the long, uncertain and often emotional journey to a genetic diagnosis. Together, they go behind the science to share what it means to live with uncertainty, how results like variants of uncertain significance (VUS) are experienced by families, and why communication and support matter just as much as genomic testing and research. The panel discuss the challenges families face when a diagnosis remains out of reach, the role of research in refining and revisiting results over time, and how collaboration between researchers, clinicians and participants could help shorten diagnostic journeys in the future. Joining Adam Clatworthy, Vice-Chair for the Participant Panel, on this episode are: Emma Baple – Clinical geneticist and Medical Director, South West Genomic Laboratory Hub  Jamie Ellingford – Lead genomic data scientist, Genomics England  Jo Wright – Member of the Participant Panel and Parent Representative for SWAN UK  Lisa Beaton - Member of the Participant Panel and Parent Representative for SWAN UK  Linked below are the episodes mentioned in the episode:  What is the diagnostic odyssey?  What is a Variant of Uncertain Significance?  Visit the Genomics England Research Summit website, to get your ticket to this years event. You can download the transcript, or read it below. Sharon: Hello, and welcome to Behind the Genes. My name is Sharon Jones and today we're bringing you a special episode recorded live from our Research Summit held in June this year. The episode features a panel conversation hosted by Adam Clatworthy, Vice-Chair of the Participant Panel. Our guests explore navigating the diagnostic odyssey, the often-complex journey to reaching a genetic diagnosis. If you'd like to know more about what the diagnostic odyssey is, check our bitesize explainer episode, ‘What is the Diagnostic Odyssey?' linked in the episode description. In today's episode you may hear our guests refer to ‘VUS' which stands for a variant of uncertain significance. This is when a genetic variant is identified, but its precise impact is not yet known. You can learn more about these in another one of our explainer episodes, “What is a Variant of Uncertain Significance?” And now over to Adam. -- Adam: Welcome, everyone, thanks for joining this session. I'm always really humbled by the lived experiences and the journeys behind the stories that we talk about at these conferences, so I'm really delighted to be hosting this panel session. It's taking us behind the science, it's really focusing on the people behind the data and the lived experiences of all the individuals and the families who are really navigating this system, trying to find answers and really aiming to get a diagnosis – that has to be the end goal. We know it's not the silver bullet, but it has to be the goal so that everyone can get that diagnosis and get that clarity and what this means for their medical care moving forwards.    So, today we're really going to aim to demystify what this diagnostic odyssey is, challenging the way researchers and clinicians often discuss long diagnostic journeys, and we'll really talk about the vital importance of research in improving diagnoses, discussing the challenges that limit the impact of emerging research for families on this odyssey and the opportunities for progress. So, we've got an amazing panel here. Rather than me trying to introduce you, I think it's great if you could just introduce yourselves, and Lisa, I'll start with you. Lisa: Hi, I'm Lisa Beaton and I am the parent of a child with an unknown, thought to be neuromuscular, disease. I joined the patient Participant Panel 2 years ago now and I'm also a Parent Representative for SWAN UK, which stands of Syndromes Without A Name. I have 4 children who have all come with unique and wonderful bits and pieces, but it's our daughter who's the most complicated. Adam:  Thank you. Over to you, Jo. Jo:  Hi, I'm Jo Wright, I am the parent of a child with an undiagnosed genetic condition.  So I've got an 11-year-old daughter. 100,000 Genomes gave us a VUS, which we're still trying to find the research for and sort of what I'll talk about in a bit.  And I've also got a younger daughter. I joined the Participant Panel just back in December. I'm also a Parent Rep for SWAN UK, so Lisa and I have known each other for quite a while through that. Adam:  Thank you, Jo.  And, Jamie, you're going to be covering both the research and the clinician side and you kind of wear 2 hats, so, yeah, over to you. Jamie:  Hi, everyone, so I'm Jamie Ellingford and, as Adam alluded to, I'm fortunate and I get to wear 2 hats. So, one of those hats is that I'm Lead Genomic Data Scientist for Rare Disease at Genomics England and so work as part of a really talented team of scientists and engineers to help develop our bioinformatic pipelines, so computational processes. I work as part of a team of scientists and software engineers to develop the computation pipelines that we apply at Genomics England as part of the National Health Service, so the Genomic Medicine Service that families get referred to and recruited to, and we try to develop and improve those. So that's one of my hats. And the second of those is I am a researcher, I'm an academic at the University of Manchester, and there I work really closely with some of the clinical teams in the North West to try and understand a little bit more about the functional impact of genomic variants on kind of how things happen in a cell. So, we can explore a little bit more about that but essentially, it's to provide a little bit more colour as to the impact that that genomic variant is having. Adam: Great, thank you, Jamie. Over to you, Emma. Emma: My name's Emma Baple, I'm an academic clinical geneticist in Exeter but I'm also the Medical Director of the South West genomic laboratory hub, so that's the Exeter and Bristol Genomics Laboratory. And I wear several other hats, including helping NHS England as the National Specialty Advisor for Genomics. Adam: Thank you all for being here. I think it's really important before we get into the questions just to ground ourselves in like those lived experiences that yourself and Jo and going through. So, Lisa, I'm going to start with you. The term ‘diagnostic odyssey' gets bandied around a lot, we hear about it so many times, but how does that reflect your experience that you've been through and what would you like researchers and clinicians to understand about this journey that you're on, essentially? Lisa: So I think ours is less an odyssey and more of a roller-coaster, and I say that because we sort of first started on a genetic journey, as it were, when my daughter was 9 weeks of age and she's now 16½ – the half's very important – and we still have no answers. And we've sort of come a bit backwards to this because when she was 6 months old Great Ormond Street Hospital felt very strongly that they knew exactly what was wrong with her and it was just a case of kind of confirmation by genetics. And then they sent off for a lot of different myasthenia panel genes, all of which came back negative, and so having been told, “Yes, it's definitely a myasthenia, we just need to know which one it is,” at 4 years of age that was removed and it was all of a sudden like, “Yeah, thanks, sorry.” And that was really hard actually because we felt we'd had somewhere to hang our hat and a cohort of people with very similar issues with their children, and then all of a sudden we were told, “No, no, that's not where you belong” and that was a really isolating experience. I can remember sort of saying to the neuromuscular team, “Well is it still neuromuscular in that case?” and there was a lot of shrugging of shoulders, and it just…  We felt like not only had we only just got on board the life raft, then we'd been chucked out, and we didn't even have a floaty. And in many ways I think I have made peace with the fact that we don't have a genetic diagnosis for our daughter but it doesn't get easier in that she has her own questions and my older children – one getting married in August who's already sort of said to me, you know, “Does this have implications for when we have children?”  And those are all questions I can't answer so that's really hard. Adam:  Thank you, Lisa. Yourself, Jo, how would you describe the odyssey that you're currently experiencing? Jo: So my daughter was about one when I started really noticing that she was having regressions. They were kind of there beforehand but, I really noticed them when she was one, and that's when I went to the GP and then got referred to the paediatrician. So initially we had genetic tests for things like Rett syndrome and Angelman syndrome, which they were all negative, and then we got referred on to the tertiary hospital and then went into 100,000 Genomes. So we enrolled in 100,000 Genomes at the beginning of 2017, and we got our results in April of 2020, so obviously that was quite a fraught time. Getting our results was probably not as you would want to do it because it was kind of over the phone and then a random letter. So, what I was told in that letter was that a variant of uncertain significance had been identified and they wanted to do further research to see if it might be more significant. So we were to be enrolled into another research project called Splicing and Disease, which wasn't active at the time because everything had been put on hold for COVID, but eventually we went into that. So, I didn't know what the gene was at that point, when I eventually got the form for going to get her bloods done…  So that went off and then that came back and the geneticist said, “That gives us some indication that it is significant.” So, since that point it's been trying to find more information and research to be able to make it a diagnosis. There have been 2 sort of key things that have happened towards that but we're still not there. So one of the things is that a research paper came out earlier this year so that's kind of a little bit more evidence, it's not going to give us a diagnosis but it kind of, you know, sits there. And the other thing is that my geneticist said, “Actually, yeah, it looks like it's an important change.”  That's as far as we've got. So we've still got work to do to make it a diagnosis or not.  Obviously if it is a diagnosis, it is still a one-of-a-kind diagnosis, so it doesn't give me a group to join or that kind of thing. But now I've got that research paper that I've read and read, and asked ChatGPT to verify that I've understood it right in some places, you know, with the faith that we put into ChatGPT (laughs), I've got a better understanding and I've got something now that I can look back on, the things that happened when my daughter was one, 2, 3, 4 and her development was all over the place and people thought that I was slightly crazy for the things I was saying, that “Actually, no, I can see what's happening.” So, it's like the picture's starting to come into focus but there's work to do. I haven't got a timeframe on that, I don't know when it's going to come together. And I always say that I'm a prolific stalker of the postman; ever since our first genetic tests you're just constantly waiting for the letters to drop through the door. So a diagnostic odyssey to me is just waiting for random events. Adam: I think what you've both kind of really clearly elaborated on is how you're the ones that are having to navigate this journey, you're the ones that are trying to piece this puzzle together, and the amount of time you're investing, all whilst navigating and looking after your child and trying to cope with the daily lived experience as well. And something you've both touched on that I'd love to draw out more is about how exactly was the information shared with you about the lack of diagnosis or the VUS or what's going on, because in our case you get this bit of paper through the post that has all these numbers and it's written in clinical speak and we had no conversation with the geneticist or the doctors. You see this bit of paper and you're reading it, scared for what the future will hold for your child, but I'd love to know like how were you communicated whilst all this is going on, how did you actually find out the next steps or any kind of future guidance. Lisa: So I think in our case we kept sort of going onto neuromuscular appointments, and I think for probably the first 5 years of my daughter's life I kind of had this very naïve thought that every time we turned up to an appointment it would be ‘the one' and then…   I think it would've been really helpful actually in those initial stages if they had said to us, “Actually, we don't know when this is going to happen, if it's even going to happen, you need to kind of prepare yourself for that.” It sounds fairly obvious to say but you don't know what you don't know. And in some ways we were getting genetic test results back for some really quite horrible things and they would tell us, “Oh it's good news, this mitochondrial disorder hasn't come up,” and so part of you is like, “Yay!” but then another part of you is thinking, “Well if it's not that what is it?” And we've very much kind of danced around and still don't really have an answer to whether it's life-limiting. We know it's potentially life-threatening and we have certain protocols, but even that is tricky. We live in North Yorkshire, and our local hospital are amazing. Every time we go in, if it's anything gastro-related, they say to me, “What's the protocol from Great Ormond Street?” and I say, “We don't have one” (laughs) and that always causes some fun. We try to stay out of hospitals as much as we absolutely can and do what we can at home but, equally, there's a point where, you know, we have to be guided by where we're going with her, with the path, and lots of phone calls backwards and forwards, and then is it going to be a transfer down to Great Ormond Street to manage it. And actually the way I found out that nothing had been found from 100,000 Genomes was in a passing conversation when we had been transferred down to Great Ormond Street and we'd been an inpatient for about 6 weeks and the geneticist said to me, “So obviously with you not having a diagnosis from the 100,000 Genomes…” and I said, “Sorry?  Sorry, what was that?  You've had the information back?”  And she said, “Well, yes, did nobody write to you?” and I said, “No, and clearly by my shock and surprise.” And she was a bit taken aback by that, but it happened yet again 2 years later (laughs) when she said, “Well you know everything's been reanalysed” and I said, “No.”  (Laughs)  And, so that's very much, it still feels an awful lot like I'm doing the heavy lifting because we're under lots of different teams and even when they're working at the same hospital they don't talk to each other. And I do understand that they're specialists within their own right, but nobody is really looking at my daughter holistically, and there are things that kind of interrelate across.    And at one of the talks I attended this morning they were talking about the importance of quality of life, and I think that is something that has to be so much more focused on because it's hard enough living without a diagnosis, but when you're living with a bunch of symptoms that, I think the best way I can describe it is at the moment we've got the spokes of the umbrella but we don't have the wrapper, and we don't know where we're going with it. We can't answer her questions, we can't even necessarily know that we're using the most effective treatments and therapies for her, and she's frustrated by that now, being 16, in her own right, as well as we are. And I'm panicking about the navigation towards Adult Services as well because at the minute at least we have a clinical lead in our amazing local paediatrician but of course once we hit and move into that we won't even have him and that's a really scary place to be, I think. Adam: Jo, is there anything you wanted to add on that in terms of how you've been communicated to whilst all this is going on? Jo: Yeah, so I think part of what makes it difficult is if you're across different hospitals because they're not necessarily going to see the same information. So obviously it was a bit of a different time when I got our results, but I got our results on a virtual appointment with a neurologist in one hospital, in the tertiary hospital, and because he could see the screen because it was the same hospital as genetics, and he said, “Oh you've got this” and then the letter came through later. When I had my next appointment with the neurologist in our primary hospital, or secondary care, whatever it's called, in that hospital, he hadn't seen that, so I'm telling him the results, which isn't ideal, but it happens quite a lot. What I think is quite significant to me is the reaction to that VUS.  I have to give it, the doctors that look after my daughter are brilliant, and I'm not criticising them in any way but their reaction to a VUS is “I'm so grateful for the persistence to get to a diagnosis.” Neurologists are a bit more like “Oh it's a VUS so it might be significant, it might be nothing.” Actually, as a patient, as in a parent, you actually want to know is it significant or not, “Do I look at it or not?” And, I mean, like I said, there were no research papers to look at before anyway until a few months ago so I didn't have anything to look at, but I didn't want to look at it either because you don't want to send yourself off down a path. But I think that collective sort of idea that once someone gets a VUS we need a pathway for it, “What do we do with it, what expectation do we set the patients up with and what is the pathway for actually researching further?” because this is where we really need the research. Adam:  Thank you, Jo. So, Emma, over to you in terms of how best do you think clinicians can actually support patients at navigating this odyssey and what's the difference between an initial diagnosis and a final diagnosis and how do you then communicate that effectively to the patients and their family?   Emma: So I think a key thing for me, and it's come up just now again, is that you need to remember as a doctor that the things you say at critical times in a patient's or parent's journeys they will remember – they'll remember it word for word even though you won't – and thinking about how to do that in the most sensitive, empathetic, calm, not rushed way is absolutely key.   And there are some difficulties with that when you're in a very high-pressure environment but it is absolutely crucial, that when you are communicating information about test results, when you're talking about doing the test in the first place, you're consenting the family, you're explaining what you're trying to do and those conditions, you balance how much information you give people.    So, you were talking earlier about “So you haven't got this diagnosis, you haven't got that diagnosis,” I often think it's…  We're often testing for numerous different conditions at the same time, I couldn't even list them all to the parents of the children or the patient that I'm testing. It's key to try and provide enough information without overwhelming people with so much information and information on specific conditions you are just thinking about as a potential.  Sometimes very low down your list actually but you can test for them.    Because people go home and they use the internet and they look things up and they get very, very worried about things. So, for me it's trying to provide bite-sized amounts of information, give it the time it deserves, and support people through that journey, tell them honestly what you think the chance of finding a diagnosis is. If you think it's unlikely or you think you know, sharing that information with family is helpful.   Around uncertainty, I find that a particular challenge. So, I think we've moved from a time when we used to, in this country, declare every variant we identified with an uncertain significance. Now, if we remember that we've all got 5 million variants in our genome, we've all got hundreds and hundreds… thousands and thousands, in fact, of variants of uncertain significance in our genetic code. And actually, unless you think a variant of uncertain significance genuinely does have a probability of being the cause of a child's or a patient's condition, sharing that information can be quite harmful to people.    We did a really interesting survey once when we were writing the guidelines for reporting variants of uncertain significance a few years ago. We asked the laboratories about their view of variants of uncertain significance and we asked the clinicians, and the scientists said, “We report variants of uncertain significance because the clinicians want them” and the clinicians said, “If the labs put the variant of uncertain significance on the report it must be important.” And of course, if you're a parent, if the doctor's told you the variant is a variant of uncertain significance of course you think it's important.    So, we should only be sharing that information, in my opinion, if it genuinely does have a high likelihood of being important and there are things that we can do. And taking people through that journey with you, with the degree of likelihood, the additional tests you need to do and explaining to them whether or not you think you will ever clarify that, is really, really key because it's very often that they become the diagnosis for the family.  Did I cover everything you think's important, both of you?  Lisa: I think the one thing I would say is that when you are patient- or parent-facing, the first time that you deliver that news to the parent… you may have delivered that piece of news multiple times and none of us sit there expecting you to kind of be overcome with emotion or anything like that but, in the same way that perhaps you would've had some nerves when, particularly if it was a diagnosis of something that was unpleasant, you know, to hold onto that kind of humanity and humility. Because for those patients and parents hearing that news, that is the only time they're ever hearing that, and the impact of that, and also, they're going on about with their day, you don't know what else they're doing, what they're juggling.    We're not asking you all to be responsible for kind of, you know, parcelling us up and whatnot but the way information is imparted to us is literally that thing we are all hanging our hats on, and when we're in this kind of uncertainty, from my personal experience I'm uncomfortable, I like to be able to plan, I'm a planner, I'm a researcher, I like to sort of look it up to the nth degree and that, and sitting in a place without any of that is, it's quite a difficult place to be. And it's not necessarily good news for those parents when a test comes back negative, because if it's not that then what is it, and that also leaves you feeling floundering and very isolated at times.  Adam: Yeah, and you touched upon the danger of like giving too much information or pushing families down a particular route, and then you have to pull them out of it when it's not that.   You talked about the experience you had, you felt like you'd found your home and then it's like, “Well, no, no, sorry, actually we don't think it's that.” And you've invested all of your time and your emotion into being part of that group and then you're kind of taken away again. So it's to the point where you have to be really sure before you then communicate to the families, and obviously in the meantime the families are like, “We just need to know something, we need to know,” and it's that real fine line, isn't it?    But, Jamie, over to you. Just thinking about the evolving nature of genomic diagnosis, what role does research play in refining or confirming a diagnosis over time?  Jamie: So it's really, really difficult actually to be able to kind of pinpoint one or 2 things that we could do as a community of researchers to help that journey, but perhaps I could reflect on a couple of things that I've seen happen over time which we think will improve things. And one of that's going back to the discussion that we've just had about how we classify genetic variants. And so, behind that kind of variant of uncertain significance there is a huge amount of effort and emotion from a scientist's side as well because I think many of the scientists, if not all, realise what impact that's going to have on the families.   And what we've tried to do as a community is to make sure that we are reproducible, and if you were to have your data analysed in the North West of England versus the South West that actually you'd come out with the same answer. And in order to do that we need guidance, we need recommendations, we need things that assist the scientists to actually classify those variants.  And so, what we have at the moment is a 5 point scale which ranges from benign to likely benign, variant of uncertain significance, unlikely pathogenic variant and pathogenic variant. It's objective as to how we classify a variant into one of those groups and so it's not just a gut feeling from a scientist, it's kind of recordable measurable evidence that they can provide to assist that classification.   So in many instances what that does is provide some uncertainty, as we've just heard, because it falls into that zone of variant of uncertain significance but what that also does is provide a framework in which we can generate more evidence to be able to classify it in one direction or another to become likely pathogenic or to become likely benign. And as a research community we're equipped with that understanding –– and not always with the tools but that's a developing area – to be able to do more about it.   What that doesn't mean is that if we generate that evidence that it can translate back into the clinic, and actually that's perhaps an area that we should discuss more. But kind of just generating that evidence isn't always enough and being able to have those routes to be able to translate back that into the hands of the clinicians, the clinical scientists, etc, is another challenge. Adam:  And how do you think we can drive progress in research to deliver these answers faster, to really try and shorten those diagnostic journeys, like what are the recommendations that you would say there? Jamie:  So being able to use the Genomics England data that's in the National Genomic Reference Library, as well as kind of other resources, has really transformed what we can do as researchers because it enables teams across the UK, across the world to work with data that otherwise they wouldn't be able to work with.   Behind that there's an infrastructure where if researchers find something which they think is of interest that can be reported back, it can be curated and analysed by teams at Genomics England and, where appropriate, kind of transferred to the clinical teams that have referred that family. And so having that pathway is great but there's still more that we can do about this. You know, it's reliant on things going through a very kind of fixed system and making sure that clinicians don't lose contact with families – you know, people move, they move locations, etc. And so, I think a lot of it is logistical and making sure that the right information can get to the right people, but it all falls under this kind of umbrella of being able to translate those research findings, where appropriate, into clinical reporting.   Adam:  Thank you. And, Emma, is there anything you would add in terms of like any key challenges that you think need to be overcome just to try and shorten the journeys as much as possible and find the answers to get a diagnosis?  Emma: I think trying to bridge that gap between some of the new technologies and new approaches that we've got that we can access in a research context and bringing those into diagnostics is a key area to try to reduce that diagnostic odyssey, so I really want to see the NHS continuing to support those sorts of initiatives.   We're very lucky, as Jamie said, the National Genomic Research Library has been fundamental for being able to reduce the diagnostic odyssey for large numbers of patients, not just in this country but around the world, and so trying to kind of look at how we might add additional data into the NGRL, use other research opportunities that we have in a more synergistic way with diagnostics I think is probably key to being able to do that.    We are very lucky in this country with the infrastructure that we've got and the fact that everything is so joined up. We're able to provide different opportunities in genomics for patients with rare conditions that aren't so available elsewhere in the world.  Adam: Great, thank you. I think we're it for time, so thank you very much to the panel. And I'd just say that if you do have any further questions for ourselves as participants then we're only too happy to pick those up. Thank you for lasting with us ‘til the end of the day and hope to see you soon.  -- Sharon: A huge thank you to our panel, Adam Clatworthy, Emma Baple, Jo Wright, Lisa Beaton and Jamie Ellingford, for sharing their insights and experiences. Each year at the summit, the Behind the Genes stage hosts podcast style conversations, bringing together researchers, clinicians and participants to discuss key topics in genomics.  If you're interested in attending a future Genomics England Research Summit, keep an eye out on our socials. If you'd like to hear more conversations like this, please like and subscribe to Behind the Genes on your favourite podcast app. Thank you for listening.    I've been your host, Sharon Jones. The podcast was edited by Bill Griffin at Ventoux Digital and produced by Deanna Barac.

It's Thursday, January 22nd, A.D. 2026. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com. I'm Adam McManus. (Adam@TheWorldview.com) By Jonathan Clark Chinese-American Christians pray for those in China Chinese-American Christians are praying for their persecuted brothers and sisters back in China. Earlier this month, Harvest Chinese Christian Church in Los Angeles held an event called “Fasting Prayer Meeting for Persecuted Churches in China.” The event comes shortly after Chinese authorities detained the leaders of Early Rain Covenant Church. The congregation, like many “unregistered” churches in China, faces relentless persecution. International Christian Concern commented, “Please pray for these house church members in China, especially those who have been imprisoned or are missing after the police raids.” 1 Corinthians 12:26 says, “If one member suffers, all the members suffer with it; or if one member is honored, all the members rejoice with it.” China's birth rate plunged to a record low in 2025 Speaking of China, the country's birth rates plunged to a record low in 2025. New data from China's National Bureau of Statistics found there were 7.92 million births last year, down 17% from 2024. The birth rate in 2025 was 5.63 per 1,000 people. Meanwhile, the death rate rose to 8.04 per 1,000 people. Despite China's recent attempts to incentivize families to have children, the population has now fallen for the fourth consecutive year. In Genesis 1:28, God commanded, “Be fruitful and increase in number; fill the Earth and subdue it.” British Christian nurse vindicated for calling a man “Mister” In the United Kingdom, a National Health Service hospital recently dropped its case against a Christian nurse. Jennifer Melle worked at St. Helier Hospital in south London. She faced suspension after referring to a man, pretending to be a woman, as “Mister.” Listen to comments she made after her vindication. MELLE: “I am deeply relieved and grateful to hear that St Helier [Hospital] has confirmed it would no longer take further action against me. This has been an incredibly long and painful journey.   “Today, I want to give thanks, first and foremost, to our Lord and Savior, Jesus Christ, who has sustained me every step of the way.” Young Canadians are planning to vote conservative Young adults in Canada are planning to vote conservative in the country's next election. A survey by Abacus Data found 50% of Canadians aged 18 to 29 would vote for the Conservative Party. Only 27% of that demographic would vote for the Liberal Party. The strongest support for the Liberals comes from people over 60. A decade of liberal polices has led to higher living costs, higher inflation, and higher taxes. Trump: “I will not use force” to get Greenland Yesterday, U.S. President Donald Trump addressed the World Economic Forum's annual meeting in Davos, Switzerland.  Notably, he announced that the United States would not use force to acquire Greenland. TRUMP: “We probably won't get anything unless I decide to use excessive strength and force, where we would be, frankly, unstoppable. But I won't do that. Okay. Now everyone's saying, ‘Oh, good!' “That's probably the biggest statement I've made because people thought I would use force. I don't have to use force. I don't want to use force. I won't use force.” President Trump also announced he will not be imposing tariffs on Denmark over the acquisition of Greenland. He wrote on Truth Social, “We have formed the framework of a future deal with respect to Greenland and, in fact, the entire Arctic Region.” Arrests coming for Minneapolis leftists who invaded church service The Trump administration is investigating anti-ICE protesters who disrupted a house of worship in Minneapolis on Sunday. Kristi Noem, the Department of Homeland Security Secretary, wrote on X, “Arrests coming. … The First Amendment protects speech and peaceful assembly – not rioting. … These agitators will be held accountable.” The Department of Justice is also investigating the incident at Cities Church. Major snowstorm hits East Coast to Rocky Mountains The National Weather Service is expecting a significant winter storm to hit a large portion of the U.S. starting Friday. Heavy snow, sleet, and freezing rain is forecast all the way from the southern Rockies to the East Coast.  Much of the U.S. is already experiencing dangerously cold weather. Over 40 million people were under cold weather alerts as of Tuesday. Even parts of Florida are under alert. 463rd anniversary of Heidelberg Catechism And finally, this week marks the 463rd anniversary of the Heidelberg Catechism. The Protestant catechism was commissioned by Frederick III, the ruler of Germany's most influential province of Palatinate. The purpose of the catechism was for instructing the youth and for guiding pastors and teachers The catechism was the product of two young Protestant scholars—Zacharius Ursinus and Caspar Olevianus. The catechism was approved by a church synod in Heidelberg, Germany and published in German on January 19, 1563. It would become the most widely used catechism of the Reformation period.  The catechism's opening question reads, “What is your only comfort in life and death?” The answer begins, “That I am not my own, but belong—body and soul, in life and in death—to my faithful Savior Jesus Christ.” Romans 14:8 says, “For if we live, we live to the Lord; and if we die, we die to the Lord. Therefore, whether we live or die, we are the Lord's.”  Close And that's The Worldview on this Thursday, January 22nd, in the year of our Lord 2026. Follow us on X or subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

Dr. Sarah Myhill has worked full time in National Health Service and independent medical practice. She has a special interest in CFS and ME. Show partners:  LMNT - Claim your free LMNT Sample Pack with any purchase by using this link Ketone-IQ - Save 30% off your subscription order plus youʼll get a free gift with your second shipment by using this link Troscriptions - 10% off your first order by using the code "JESSE" at checkout Quicksilver Scientific - 15% off your first order by using the code "jesse15" at checkout Show notes: https://jessechappus.com/688

Send Vikki any questions you'd like answered on the show!A critical inner voice is one of the most common and difficult experience as a PhD student or academic. In this episode, you get to hear me coaching TWO of my current students in the PhD Life Coach membership, who are both part time PhD students while holding down demanding careers in our National Health Service. It runs like one of our group coaching sessions, where they each get coached AND hear each other get coached on self-talk, prioritisation, and compassion. If you have a critical inner voice, or if you've ever wondered about the benefits of group coaching, then you're in the right place!If you liked this episode, you should check out my episode on How Winnie the Pooh can help you manage your mind.****I'm Dr Vikki Wright, ex-Professor and certified life coach and I help everyone from PhD students to full Professors to get a bit less overwhelmed and thrive in academia. Please make sure you subscribe, and I would love it if you could find time to rate, review and tell your friends! You can send them this universal link that will work whatever the podcast app they use. http://pod.link/1650551306?i=1000695434464 I also host a free online community for academics at every level. You can sign up on my website, The PhD Life Coach. com - you'll receive regular emails with helpful tips and access to free online group coaching every single month! Come join and get the support you need.

In this episode, we tackle the contentious issue of socialized medicine in America, with a spotlight on the failures of the National Health Service in Great Britain. John Solomon welcomes former British Prime Minister Liz Truss, who shares her firsthand experiences and insights into the pitfalls of government-run healthcare. We also discuss the implications of free speech in today's political climate with author Stuart Brotman. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this special end-of-year episode of Behind the Genes, host Sharon Jones is joined by Dr Rich Scott, Chief Executive Officer of Genomics England, to reflect on the past year at Genomics England, and to look ahead to what the future holds.  Together, they revisit standout conversations from across the year, exploring how genomics is increasingly embedded in national health strategy, from the NHS 10-Year Health Plan to the government's ambitions for the UK life sciences sector. Rich reflects on the real-world impact of research, including thousands of diagnoses returned to the NHS, progress in cancer and rare condition research, and the growing momentum of the Generation Study, which is exploring whether whole genome sequencing could be offered routinely at birth.  This episode offers a thoughtful reflection on how partnership, innovation, and public trust are shaping the future of genomic healthcare in the UK and why the years ahead promise to be even more exciting.  Below are the links to the podcasts mentioned in this episode, in order of appearance:  How are families and hospitals bringing the Generation Study to life? How can cross-sector collaborations drive responsible use of AI for genomic innovation? How can we enable ethical and inclusive research to thrive? How can parental insights transform care for rare genetic conditions? How can we unlock the potential of large-scale health datasets? Can patient collaboration shape the future of therapies for rare conditions? https://www.genomicsengland.co.uk/podcasts/what-can-we-learn-from-the-generation-study “There is this view set out there where as many as half of all health interactions by 2035 could be informed by genomics or other similar advanced analytics, and we think that is a really ambitious challenge, but also a really exciting one.”  You can download the transcript, or read it below. Sharon: Hello, and welcome to Behind the Genes.   Rich: This is about improving health outcomes, but it's also part of a broader benefit to the country because the UK is recognised already as a great place from a genomics perspective. We think playing our role in that won't just bring the health benefits, it also will secure the country's position as the best place in the world to discover, prove, and where proven roll out benefit from genomic innovations and we think it's so exciting to be part of that team effort.  Sharon: I'm Sharon Jones, and today I'll be joined by Rich Scott, Chief Executive Officer at Genomics England for this end of year special. We'll be reflecting on some of the conversations from this year's episodes, and Rich will be sharing his insights and thoughts for the year ahead. If you enjoyed this episode, we'd love your support, so please subscribe, rate, and share on your favourite podcast app. So, let's get started.  Thanks for joining me today, Rich. How are you?  Rich: Great, it's really good to be here.   Sharon: It's been a really exciting year for Genomics England. Can you tell us a bit about what's going on?  Rich: Yeah, it's been a really busy year, and we'll dive into a few bits of the components we've been working on really hard. One really big theme for us is it's been really fantastic to see genomics at the heart of the government's thinking. As we'll hear later, genomics is at the centre of the new NHS 10-year health plan, and the government's life sciences sector plan is really ambitious in terms of thinking about how genomics could play a role in routine everyday support of healthcare for many people across the population in the future and it shows a real continued commitment to support the building of the right infrastructure, generating the right evidence to inform that, and to do that in dialogue with the public and patients, and it's great to see us as a key part of that.  It's also been a really great year as we've been getting on with the various programmes that we've got, so our continued support of the NHS and our work with researchers accessing the National Genomic Research Library. It's so wonderful to see the continued stream of diagnoses and actionable findings going back to the NHS. It's been a really exciting year in terms of research, publications. In cancer, some really exciting publications on, for example, breast cancer and clinical trials. Really good partnership work with some industry partners, really supporting their work. For me, one of the figures we are always really pleased to see go up with time is the number of diagnoses that we can return thanks to research that's ongoing in the research library, so now we've just passed 5,000 diagnostic discoveries having gone back to the NHS, it really helps explain for me how working both with clinical care and with research and linking them really comes to life and why it's so vital.   And then, with our programmes, it's been great to see the Generation Study making good progress. So, working with people across the country, more than 25,000 families now recruited to the study, and we're beginning to hear about their experiences, including some of the families who've received findings from the programme. It's really nice to see and hear from Freddie's family, who talked to the press a bit about the finding that they received. Freddie was at increased risk of a rare eye cancer, and really pleasingly, it was possible to detect that early through the screening that was put in place. Again, it really brings to life why we're doing this, to make a difference and improve health outcomes.  Sharon: That's an incredible 12 months. Diving into that Generation Study piece and for listeners who don't know what that is, it's a research study in partnership with the NHS that aims to sequence the genomes of 100,000 newborn babies. On an episode from earlier in the year, we had mum, Rachel Peck, join the conversation, whose baby Amber is enrolled on a study. Let's year from Rachel now.  Rachel: From the parents' point of view, I guess that's the hardest thing to consent for in terms of you having to make a decision on behalf of your unborn child. But I think why we thought that was worthwhile was that could potentially benefit Amber personally herself or if not, there's the potential it could benefit other children.  Sharon: Consent has been such a big area of focus for us, Rich, and Rachel touches on that complexity, you know, making a decision on behalf of her unborn child. Can you talk a bit about our approach to consent in the Generation Study and what's evolving in that model?  Rich: Yeah. It's been for the whole study, really, starting out asking a really big question here, what we're aiming to do is generate evidence on whether and if so, how whole genome sequencing should be offered routinely at birth, and that's responding to a really ill need that we know that each year thousands of babies are born in the UK with treatable rare conditions. We will also need to see if whole genome sequencing can make a difference for those families, but we realise to do that, as with all screening, that involves testing more people than are going to benefit from it directly themselves. So, you have to approach it really sensitively. There's lots of complicated questions, lots of nuance in the study overall. One of them is thinking really carefully about that consent process so that families can understand the choices, they can understand the benefits and risks. This is still a research study. We're looking to understand whether we should offer this routinely. It's not part of routine care at this point. The evidence will help decision-makers, policymakers in the future decide that.  At the beginning of the programme, we spent a lot of time talking to families, talking to health professionals who understand the sorts of decisions that people are making at that time of life, but also are experts in helping think about how you balance that communication. That involved, as I say, a lot of conversations. We learnt a lot, lots of it practical stuff, about the stage of pregnancy that people are at when we first talk to them about the study, so that people aren't hurried and make this decision. What we've learnt in the study, right from the outset, is talking to people from midway through the pregnancy so that they really have time to engage in it and think about their choice. So, it's an important part of getting the study design right so that we run the study right. It's also a really crucial element of the evidence that will generate from the study so that we can understand if this is something that's adopted, how should we communicate about it to families. What would they want to know? What's the right level of information and how do we make that accessible in a way that is meaningful to people from different backgrounds, with different levels of interest, different accessibility in terms of digital and reading and so on. There's a lot that we've learnt along the way and there's a lot that we're still learning. And as I say, important things that we'll present as evidence later on.  Sharon: Thank you. It's fascinating there are so many moving parts and a lot to consider when you're building the design of a programme like this or study like this.  Earlier in the year you had a great conversation with Karim Beguir about the developments of AI in genomics. Let's revisit that moment.  Karim: We live in an extraordinary time. I want to emphasise the potential of scientific discovery in the next two or three years. AI is going to move, let's say, digital style technologies like coding and math towards more like science and biology. In particular, genomics is going to be a fascinating area in terms of potential.  Sharon: So, Karim talks about AI moving from maths and coding into biology. Why is genomics such a natural area for AI?  Rich: It's really fascinating. I think it links a lot to how we think about genomics and how you get the most value in terms of health benefit and sort of the progress that we can see could come through genomics more generally. So, your genome, which is your DNA code, written in 3 billion little letters across each one of us, one copied from mum, one copied from dad, even just our genomic code of one person is a large amount of data. That is just part of the story because we're not just interested in DNA for DNA's sake, this is about thinking about health and how we can improve health outcomes. So, it's also thinking about the other sorts of information that needs to link to genomic data to make a difference. Whether that's just to provide routine healthcare with today's knowledge, or whether it's about continuing to learn and discover.  As I mentioned at the beginning, I think a really important part of this whole picture is we've learnt a lot in the last 20/30/40 plus years about genomics. It's incredible how much progress has been made, and we're really just scratching the surface. Take rare disease and the progress that's been made there, it's wonderful how many more families we're able to help today. We know that many thousands of families we still can't find a diagnosis for when we know that there is one there for many of them. That theme of ongoing learning is at the centre of all of our work, and that will continue as we look about broader uses of genomics in other settings beyond rare conditions and cancer. It's also that ongoing learning, but also the amount of, at the moment, manual steps that are required in some of the processes that we need to, for example, find a diagnosis for someone or to make sure the tools that we use are the most up to date, the most up to date with the medical literature, for example. AI is a tool that we're, as the whole of the society, we're beginning to see how it can play a role. We see it as important today for some of the just really practical things. I mentioned it, staying up to date with the medical literature, making sure that we and our systems are aware of all of the knowledge that's coming in from around the world. It's got real potential there.  I think the biggest bottom line here is that it's got the potential to be a really important tool in terms of our ongoing learning and improvement. I'm a doctor by background, the human intelligence alone is fantastic, it's moved us a long way, but we know it also has tremendous blind spots. AI has the potential to complement us there. I guess another thing to really call out here, AI isn't a panacea, it's not suddenly going to answer all of the questions. And, just like human intelligence, it will have its own biases, have its own strong points, and less strong points.  One of the things we're really committed to is working with people like Karim, and many others, to understand where AI could make a difference, to test it, to generate evidence on how well it works and an understanding in all sorts of ways about how that might play out. And, make sure that as AI becomes a tool, that we in genomics, but also in other areas, we understand its strong points and where we need to be more careful and cautious with it. That's a really important part of what we're going to be doing in the coming years here, is making sure that we can maximise the impact of it, but also be confident, so that we can explain to people whose data we might use it on how we're doing it and what it's bringing.  Sharon: Thanks Rich. It's definitely a fast-moving conversation of which we really want to be part of. One of the things that's come up again and again this year is participation and co-production. Let's hear quote that really captures that.  Bobbie: In an earlier conversation with Paul, which you might find surprising that it's stuck with me so much, he used the word ‘extractive'. He said that he'd been involved in research before and looking back on it, he had felt at times it could be a little bit extractive. You come in, you ask questions, you take the data away and analyse it, and it might only be by chance that the participants ever know what became of things next. One of the real principles of this project was always going to be co-production and true collaboration with our participants.  Sharon: That was Professor Bobbie Farsides talking about moving away from extractive research towards true co-production. How are we making that shift in practice here at Genomics England?  Rich: It's a great question. It's one of the areas where I think we've learnt most as an organisation over the years about how really engaging from the beginning with potential participants in programmes, participants who join our programmes, people who are involved in delivering our programmes and healthcare is so important at the beginning. I mentioned earlier the work to think about the consent process for the Generation Study, and that's one of the areas where I think from our first programme, 100,000 Genomes Project, we learnt a lot about how to do that well, some of the pitfalls, some of the bits that are most challenging. And really, right from the start of our programmes, making sure that people who will potentially benefit from the programmes, potentially join them, can be part of that engagement process, and really part of the design and the shaping of the research questions, the parameters around research, but also the materials and how people will engage with them. And that's one of the key capabilities we have internally as an organisation, so we work with partners externally, but also it's a really key part of the team that we have at Genomics England.  Sharon: So, whilst Bobbie talked about moving away from research that can feel one-sided and towards true collaboration, in another episode, Lindsay, a parent of a child with a rare condition, reflected on what that change really means for families and how it's empowering to see their voices and experiences shaping future treatments.  Lindsay: Historically, there's been a significant absence of a patient voice in rare disease research and development. And knowing that that's changing, I think that's really empowering for families. To know that professionals and industry are actually listening to our stories and our needs and really trying to understand, that offers much greater impact on the care and treatments of patients in the future.  Sharon: So, what role do you see participants as partners in shaping the next phase of Genomics England's work?  Rich: So, as you probably detected from my last answer, we see it as absolutely vital. One of the really exciting things here at Genomics England, we've had a participant panel from very early in our life as an organisation. That's one really important route to us at the heart of our organisation, part of our governance, making sure that participants representing all sorts of parts of our programme, but rare conditions being a really large focus for us. And I think, what's so striking as someone with a medical and a research background can see how I think historically medics and researchers have sometimes not known, sort of maybe been a bit scared about knowing how to involve participants from the outset. Often, because they're worried that they might ask the wrong questions in the wrong way, they just don't have the tools.   One of the things I often say now to people we work with is one of the most empowering and positive experiences we have at Genomics England is the power of our participants helping to, right from the beginning, shape what the questions are that we should be asking. Realise some of the challenges that you can't possibly, if you're not in their shoes, understand are the most important to really shape how we prioritise our work internally, the problems that we need to solve first, how we think about some of the practical impacts on people's lives that, again, without hearing from their voice you just wouldn't know. And again, to help our researchers, people accessing data in the National Genomic Research Library, helping them make sure that they involve participants in their work and the confidence and tools to do that.  Sharon: That's great, thank you. Another big theme this year has been collaboration across the NHS, academia, and industry. Dr Raghib Ali puts this really well.  Raghib: There are areas where academia and the NHS are very strong, and there are areas where industry is very strong, and why working together, as we saw, you know, very good examples during the pandemic with the vaccine and diagnostic tests, etc., a collaboration between the NHS, academia, and industry leads to much more rapid and wider benefits for our patients and, hopefully, in the future for the population as a whole in terms of early detection and prevention of disease.  Sharon: So, how does collaboration fit into the 10-year health plan and what's next for 2026 in that space, Rich?  Rich: I think one of the most enjoyable parts of my role at Genomics England and our role as an organisation is the fact that we see ourselves very much as part of a, sort of team across the UK and in fact internationally in terms of delivering on the potential we see for genomics. So, we have a vision as an organisation, which has been the same the last 5 or so years, which is a world where everyone can benefit from genomic healthcare. In fact, that vision is now shared by the NHS from a genomics perspective, and really demonstrably, the 2 parts of the system absolutely pointing in the same direction. And when we've been thinking, looking forward with that 10-year lens on it, what we always like to do, and I think it's a real privilege to be able to do, because we're here in the UK, because we have a National Health Service, because there's been that long-term commitment from government on genomics and really taking a long-term investment view there, and because of so many other parts of the ecosystem, other experts who access data in the National Genomic Research Library, research organisations like Our Future Health, UK Biobank, all teaming together, and the expertise that's there in genomics more broadly. So we've, if you like, worked back from what the UK could do as whole, and in the 10-year health plan, as I said earlier, genomics is at the heart of that.  There's a double helix on the front cover and, in fact, on the watermark on almost every page. And, there's this view set out there where as many as half of all health interactions by 2035 could be informed by genomics or other similar advanced analytics. And we think that that's a really ambitious challenge. We see a really important role for us, as Genomics England, in contributing to that, but it's very much a team effort. Our role is around where we have the biggest capabilities, so around building and running digital infrastructure at a national scale for healthcare delivery and for research, to building evidence to inform future policies, so running programmes like the Generation Study to inform future policy. And really, as part of that, that evidence piece, being driven by engagement, ethics, and work on equity, to really make sure that evidence that future policy can be built on is informed by a fully rounded view. We think if we do that right that we could as a country with others, the NHS, research organisations, many others could live up to that ambition that's set out there in the 10-year plan.   And the 10-year plan is really clear, and government is really clear that this is about improving health outcomes. But it's also part of a broader benefit to the country because the UK is recognised already as a great place from a genomics perspective. We think playing our role in that won't just bring the health benefits, it also will secure the country's position as the best place in the world to discover, prove and where proven role out benefit from genomic innovations. And we think it's so exciting to be part of that team effort.  Sharon: So, Genomics England's refreshed mission and direction of travel is really setting out how we move from research to routine care, and how we embed genomics across the health system. Carlo Rinaldi captured the idea perfectly, imagining a future where diagnosis and hope arrive hand in hand.  Carlo: My dream is that in five to ten years' time an individual with a rare disease is identified in the clinic, perhaps even before symptoms have manifested. At that exact time the day of the diagnosis becomes also a day of hope, in a way, where immediately the researcher, the genetic labs, flags that specific variant, that specific mutation. We know exactly which is the best genetic therapy to go after.   Sharon: And Rich, what are your thoughts on that?  Rich: I think Carlo captures it really well. And for us, I think a really big theme is for that potential for genomics to make a difference, a continued and in fact increased difference for people with rare conditions and cancer, areas where it's already making a difference, but also with the potential to make a much broader impact for people across the population. The real theme is embedding genomics into routine care, making it something that you don't need to know that you're seeing an expert in genomics to benefit from it, really make sure that those benefits can be felt as just part of routine care. It's not something separate where we recognise that the best healthcare is healthcare that's supported by all sorts of inputs, with genomics being a key part of that, and that we can continue to learn as we do that. So that with people's consent, with their understanding of how their data is being used, we know that if we don't have the best answer for them today, we give the best answer we can today, and we can continue to learn, and they can benefit from that in the future.   I'm a rare disease doctor by background, and one of the really most enjoyable parts of my job is seeing that come to practice. In the last year or so I've had a number of families where I've been seeing the family for years, and a researcher accessing data in the National Genomic Research library has found an answer that we've not been able to find for maybe their child's whole life, and then finally we're able to feed it back. Seeing that come to life is just so wonderful, and I think gives us a bit of a blueprint for how things could work more generally.  Sharon: That's great. I mean, what a feeling for those families who do get those answers. As we look ahead to 2026 and beyond, the conversation is starting to include prevention, using genomics not just to diagnose conditions but to predict and treat and even prevent them. Alice Tuff-Lacey summarised this nicely in an episode about Generation Study.  Alice: This is quite an exciting shift in how we use whole genome sequencing, because what we're talking about is using it in a much more preventative way. Traditionally where we've been using it is diagnostically where we know someone's sick and they've got symptoms of rare condition, and we're looking to see what they might have. What we're actually talking about is screening babies from birth using their genome to see if they're at risk of a particular condition. And what this means is this raises quite a lot of complex ethical, operational, and scientific and clinical questions.  Sharon: Rich, when you think about 2026, what's your biggest hope for where we'll be this time next year?  Rich: I think it's a really exciting time. As you can tell from how we've been speaking, I'm really excited about the direction of travel and how over the next 5 and 10 years we can really make a transformational shift because of how well placed we are in the UK from a genomics perspective. Where we are with today's knowledge, where we could be because of the continued government and NHS commitment to genomics being at the heart of this, if we build the right infrastructure, if we generate the right evidence to inform what's adopted, I think we're in a really exciting place.  From a 2026 perspective, I think what we're really committed to is continuing to do the work, the day-by-day-by-day work that is to build that incrementally. So, a really big focus for us is continuing to support the NHS and making sure researchers can access data, so that flow of answers for families can continue and grow, accelerate, to continue delivering the Generation Study because it's a really important part of that wider jigsaw to generate the evidence that can inform future policy on whether this is something that's adopted and offered routinely to every child when they're born.  I think a really important time now that the government's provided the opportunity for us as a team, as a UK genomics and life sciences ecosystem, is to really put in place some of the next steps, the building blocks that can take us towards that 10-year vision. So for us also, a really important part of the year is beginning the design process for an adult population genomics programme, where we're looking at what evidence it's important that we can provide that's complementary to different work around by others in the ecosystem that needs to be there if we're going to think about that potential broader use of genomics.  Sharon: That's great. It sounds like another exciting year ahead. So, we're going to wrap up there. Thank you to Rich Scott for sharing your reflections on the key milestones this year, and for your thoughts on the year ahead. Thanks, Rich.  Rich: Thanks very much for having me.  Sharon: If you enjoyed today's episode, we'd love your support, so please subscribe, share, and rate us on wherever you listen to your podcasts. I've been your host, Sharon Jones. This podcast was produced by Deanna Barac and edited by Bill Griffin at Ventoux Digital. Thank you for listening. 

Dr. Alexandra Markou-Guzman is a pediatric dentist who works in a public health center treating children from a Hasidic Jewish population in New York City. She shares her experience working with this population, and the cultural challenges that come with it. We discuss some of the unique dental considerations that come into play with treatment planning and working with these families. Dr. Alex is a recent graduate of an NYU residency. She shares how she was able to apply for and receive a National Health Service scholarship to help pay for school. By qualifying for this scholarship and completing two years of work in public health, she was able to significantly reduce her student loan burden.

Welcome to the Planet MicroCap Podcast's Due Diligence series. I'm your host, Robert Kraft. My guest today is Dan Goldberger, CEO of electroCore (NASDAQ: ECOR). electroCore is a commercial-stage neuromodulation company developing a suite of non-invasive vagus nerve stimulation devices—delivering a two-minute therapy session designed to rebalance the autonomic nervous system. Built around its nVNS platform, the company operates across three channels: prescription medical devices for headache and migraine, the fast-growing Truvaga direct-to-consumer wellness brand, and a specialized military and government division built around its ruggedized tac-stim product.   Founded in 2006 as a non-invasive alternative to implanted vagus nerve stimulators, electroCore has evolved into a multi-indication business with seven FDA authorizations for headache, serving major customers like the U.S. Department of Veterans Affairs and the UK's National Health Service. I invited Dan to the show to discuss all of this, as well as: How nVNS platform works and the science behind vagus nerve modulation electroCore's evolution from implanted alternatives to multi-channel neuromodulation The prescription business model across the VA, NHS, and managed care Truvaga's growth in the wellness market and why awareness is the primary competitor The tac-stim military program and its role as a meaningful revenue stream Strategic priorities heading into 2026—profitability, capital allocation, and commercial execution Challenges around insurance coverage and overcoming the “chicken and egg” problem The path toward becoming a $150–200 million business and the long-term vision for the platform For more information about electroCore, please visit: https://www.electrocore.com/ This podcast was recorded and is being made available by SNN, Inc. (together with its affiliates and its and their employees, “SNN”) solely for informational purposes. SNN is not providing or undertaking to provide any financial, economic, legal, accounting, tax, or other advice in or by virtue of this podcast. The information, statements, comments, views, and opinions provided in this podcast are general in nature, and such information, statements, comments, views, and opinions, and the viewing of/listening to this podcast are not intended to be and should not be construed as the provision of investment advice by SNN. The information, statements, comments, views, and opinions expressed in this podcast do not constitute and should not be construed as an offer to buy or sell any securities or to make or consider any investment or other course of action. The information, statements, comments, views, and opinions expressed in this podcast (including by guest speakers who are not officers, employees, or agents of SNN) are not necessarily those of SNN and may not be current. Reference to any specific third-party entity, product, service, materials, or content does not constitute an endorsement or recommendation by the SNN. SNN assumes no responsibility or liability for the accuracy or completeness of the content contained in third party materials or on third party sites referenced in this podcast or the compliance with applicable laws of such materials and/or links referenced herein. The views expressed by guest speakers are their own and their appearance on this podcast does not imply an endorsement of them or any entity they represent. SNN does not make any representation or warranty as to the accuracy or completeness of any of the information, statements, comments, views, or opinions contained in this podcast, which may include forward-looking statements where actual results may differ materially. SNN does not undertake any obligation whatsoever to provide any form of update, amendment, change, or correction to any of the information, statements, comments, views or opinions set forth in this podcast. SNN EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY OR RESPONSIBILITY FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR OTHER DAMAGES ARISING OUT OF ANY INDIVIDUAL'S USE OF, REFERENCE TO, RELIANCE ON, OR INABILITY TO USE, THIS PODCAST OR THE INFORMATION PRESENTED IN THIS PODCAST. By accessing this podcast, the listener acknowledges that the entire contents and design of this podcast, are the property of SNN, or used by SNN with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this podcast may save and use information contained in the podcast only for personal or other non-commercial educational purposes. No other use, including without limitation, reproduction, retransmission, or editing of this podcast may be made without the prior written consent of SNN.

In this week's episode we're taking a close look at the New Hospital Programme, a programme which has been described as perhaps the most ambitious National Health Service infrastructure investment in decades.The NHP programme is tasked with delivering a new generation of state-of-the-art hospitals across England. At its core is Hospital 2.0, a standardised, repeatable and industrialised approach to hospital design and delivery that promises greater certainty, faster construction, improved quality, predictable costs, and cutting-edge clinical environments. To explain the programme and how it will be delivered, I am joined by Doug Baldock, Technical Services Director, and Emily King, Director of Industrialisation at the NHP, two leaders central to shaping the technical, commercial and industrial strategy underpinning Hospital 2.0. And with a long-term pipeline backed by rolling five-year funding envelopes averaging around £3 billion a year from 2030, the programme aligns with the Government's wider Industrial Strategy and aims not only to modernise the NHS estate but to boost innovation, strengthen supply chains and support economic growth across the UK.The scale of this challenge is immense: dozens of complex hospital schemes, varied site conditions, urgent RAAC rebuilds – and, of course, the need to rebuild public and industry confidence after years of delay and uncertainty. Yet with clearer planning assumptions, a 12-year £37bn Hospital 2.0 Alliance procurement, and deep engagement with suppliers, the programme now seeks to unlock the capability and investment needed for a sustainable long-term programme.Well let's find out what it means in reality..Resources New Hospital Programme: Plan for ImplementationGovernment hospital investment press release Supplier Guide.Egan review 1998Latham review 1994

There is a world of difference between the NHS from its beginnings in 1948 and the NHS as it is now. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Ruth Chambers OBE, co-director of Raparu Consult CIC and a visiting professor at Staffordshire University, for a conversation on her book, “Our NHS for better or worse?”. Chambers discusses her personal experience as a GP in the NHS, including the discrimination she faced as a woman, and analyses the notion of ‘burden' in respect of the National Health Service, as well as differences in mental health care now and her proposed ‘Prescription for Change'. You can listen to episode 228 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

This special Christmas episode captures a moment in time – a warm and reflective conversation with my dad, Gary, recorded with his loyal sidekick Hobbs the dog, who makes his presence known but settles down after about 5 minutes. With Christmas approaching, I wanted to step back and explore what the festive season felt like in the 1950s – when Dad was growing up in a terraced house in Leeds, the National Health Service was brand new, and festivities were shaped far more by family and imagination than by spending. Across the episode, Dad paints a vivid picture of Christmas Eve plays staged in their tiny kitchenette, paper-chain decorations, walk-to-grandma traditions, and the excitement of having the whole family under one roof. We talk about presents, pubs you couldn't take children into, cars with no seatbelts, and rituals that meant far more than the gifts themselves. It is also a gentle reminder that the memories that last are the simplest ones – cooking together, laughing together, being together. As Dad says, the details stay with you forever, long after the people have gone. If you need a moment of nostalgia, grounding or perspective in the build up to Christmas, this is a lovely listen.

In case you didn't see our major announcement this week… The OCTOBER 7 play is having its most high profile performance to date! You won't believe where it will be showing next. Hint: It's right in the belly of the beast and we want to see you there. All will be revealed soon. And just when we thought the trans madness was dying in the UK, we discover that the Dr Frankensteins/Mengeles of the world are alive and well in that country's National Health Service. They want to recruit 250 humans for gender experiments.Oh but don't worry, these patients/victims will be at least at the ripe old age of 10, and totally understand what they're in for. Of course they can give informed consent. Not. Watch the Scoop this week to hear about the latest attack on children whose bodies are being destroyed on the altar of progress. And our home country of Ireland is constantly proving that it is the most anti-Semitic country in Europe. Now they've somehow sunk to a new low by deciding to rename a park, which was dedicated to a local Jewish hero. Dublin City Council's scheme was thwarted by a technicality, for now… Watch this week's episode to get all of the infuriating details. You can also learn more through Phelim's coverage on Substack(linked below).And in Crazy California, we reveal why the homeless problem will never be solved. It's because Democrats are making just too much money maintaining the problem - as the rest of us suffer from their corruption.And is Ann McElhinney safe to drive on the nation's roads? According to the DMV - she is a danger. If it's true, then how did hundreds of thousands of Indian immigrants get truck driving licenses when they obviously were not qualified? Watch this week to hear our answer. And we have a new “no recipe recipe” for salmon this week. Watch this week to learn how to make one of Ann's favorite dishes. You will also need Ann's recipe for Kale Salad(linked below) for a side and we let you in on our secret for the perfect French Fries. For those who missed last week's episode, we looked back at the first Thanksgiving episode of the ANN AND PHELIM SCOOP when we interviewed our dear friend, Dennis Prager. Dennis, who has suffered a catastrophic injury, is the embodiment of the spirit of Thanksgiving and our interview with him and hearing his message promoting happiness and gratitude still warms the heart. Dennis has had a tough time since then, but he says he is still thankful to be alive. As you know we read all of your comments and loved all of the encouragement that you sent his way. We will be passing on your messages to Dennis.Watch the episode where we will read some of those comments on the air. Please keep leaving comments wherever you get our content and you may get a shoutout on our show. While you will be getting this message after Giving Tuesday, we do ask that you go to Unreportedstorysociety.com(also linked below) and give what you can so that we can keep producing new projects, and keep our latest projects like OCTOBER 7 the play running. We are a 501(c)(3) so your donation will be tax deductible.If you want to see OCTOBER 7 the play come to a location near you please donate at October7theplay.com(also linked below). And if you are already doing your Christmas shopping and waiting in another loooong line at the mall, please consider subscribing to our Stories.io substack(linked below) so that you can get informed and engaged in matters that we talk about beyond just our weekly show.To donate click here:To subscribe to our substack click here:To help us continue to tour OCTOBER 7 the play, please go here:http://October7thePlay.com To read Phelilm's latest substack about anti-Semitism in Ireland click here. To make Ann's kale salad recipe click here:

Dr. Colin Robertson suggests we look at our lives on a day to day basis making sure that we are "earning our dopamine" in a way that creates long term benefits, mixing nature into our daily routine, and creating health that allows us to wake up painless.Some key takeaways from the conversation:Health, wellness, and fitness are fundamental building blocks of a life worth living, more important than financial wealthPhysical health enables people to fully experience life and create lasting memoriesThe gut is "the center of the human universe" - optimizing gut health has multiplying effects on all other aspects of healthNatural, unprocessed foods are essential for proper gut function and overall healthActive experiences in nature create deeper, more lasting neural connections than passive screen-based activitiesTesting gut health provides objective data to guide personalized health improvementsDr. Colin Robertson (Dr. Col) is an environmental physiologist with a PhD in Exercise Physiology who helps translate cutting-edge sport science into practical strategies for athletes, adventurers, and everyday health seekers. For more than two decades, he has helped shape health strategies and standards for organizations worldwide, including EuropeActive, UKactive, and the National Health Service. A specialist in human performance and sports science, he has coached and prepared global adventurers to tackle extraordinary challenges, from climbing Everest to rowing the Atlantic, and supported athletes in strength and conditioning across various sports, including rugby, wrestling, and wheelchair basketball, in national and international competitions. He is an accredited Strength and Conditioning Coach (UKSCA), accredited Kinanthropometrist, and a qualified Nutritionalist, blending elite-level sport science and clinical health research into practical lifestyle strategies. His research is widely published in peer-reviewed scientific journals, including co-authoring the notable Sleep and the Athlete: Narrative Review and 2021 Expert Consensus Recommendations (British Journal of Sports Medicine, 2021). He also co-hosts the Common Knowledge podcast, a go-to channel for useful and meaningful health and lifestyle information that is free and accessible to everyone. Zinzino is a global health tech company from Scandinavia, pioneering products and services in the health and wellness space for over two decades. Driving a new standard in personal health, the company's test-based, personalized nutrition approach provides tools for a healthier future by enabling individuals to take charge of their personal well-being through science-based insights and targeted solutions. Offerings include a portfolio of advanced at-home health tests and an extensive range of nutritional supplements scientifically proven to meet individual needs. Visit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys

The UK's consumer healthcare industry association, PAGB is publishing a series of blog posts for Self-Care Week – an annual awareness campaign in the UK organized by the Self Care Forum, held this year from 17-23 November. In this second part of a special episode of HBW Insight's Over the Counter podcast, we catch up with the association's CEO Michelle Riddalls, to talk about what the association is doing to promote digital health. As part of the UK government's plans for reforming the country's National Health Service, PAGB is asking for the widely used UK NHS app to not only advise people on how to self-care but also to take users to OTC brand websites that can help them to self-manage their conditions appropriately. We also discuss the advantage of having digital apps and self-care information generally linked to trusted umbrella brands. Timestamps 2:00 – PAGB's digital health strategy 6:00 – The NHS app and self-care brands 12:00 – Self-care apps 15:30 – The importance of brands Guest Bio Michelle Riddalls OBE is chief executive officer of PAGB, the consumer healthcare association, which represents the manufacturers of branded OTC medicines, self-care medical devices and food supplements in the UK. Prior to joining PAGB, Riddalls was director of regulatory affairs for the Northern European Cluster at Pfizer Consumer Healthcare, where she was integral in the highly successful POM to GSL reclassification of Nexium Control and the Viagra Connect POM to P switch. Michelle has been recognized across a number of industry awards, including the Women in Trade Powerlist in 2024, and was awarded an OBE for outstanding services to consumer health in the King's 2025 New Year Honours.

Peter McCue worked for many years as a clinical psychologist in the National Health Service in the UK. He lives in Scotland. His qualifications include a Ph.D., from the University of Glasgow, awarded for a thesis based on research into the nature of hypnosis. His interest in psychical research goes back decades. He believes that paranormal phenomena occur, and that many UFO experiences are genuinely anomalous. He contends that if we want to obtain a comprehensive understanding of ourselves and the nature of reality, these enigmatic phenomena can't be ignored. Peter is the author of a recently published book, entitled Zones of Strangeness: An Examination of Paranormal and UFO Hot Spots.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-x-zone-radio-tv-show--1078348/support.Please note that all XZBN radio and/or television shows are Copyright © REL-MAR McConnell Meda Company, Niagara, Ontario, Canada – www.rel-mar.com. For more Episodes of this show and all shows produced, broadcasted and syndicated from REL-MAR McConell Media Company and The 'X' Zone Broadcast Network and the 'X' Zone TV Channell, visit www.xzbn.net. For programming, distribution, and syndication inquiries, email programming@xzbn.net.We are proud to announce the we have launched TWATNews.com, launched in August 2025.TWATNews.com is an independent online news platform dedicated to uncovering the truth about Donald Trump and his ongoing influence in politics, business, and society. Unlike mainstream outlets that often sanitize, soften, or ignore stories that challenge Trump and his allies, TWATNews digs deeper to deliver hard-hitting articles, investigative features, and sharp commentary that mainstream media won't touch.These are stories and articles that you will not read anywhere else.Our mission is simple: to expose corruption, lies, and authoritarian tendencies while giving voice to the perspectives and evidence that are often marginalized or buried by corporate-controlled media

#MEDICALINNOVATION #OLYMPICSWIMMING #championmindset This is an inspirational keynote presentation on October 6, 2025, at the Opening Ceremony of the 2025 Medical lnnovation Olympics from Chris Cook, double Olympian swimmer, double Commonwealth Games Champion, World Championship Bronze Medalist, motivational speaker at companies such as Microsoft and some of the largest health systems across the globe, and consultant to the U.K.'s government's National Health Service.Chris shares three specific personal stories that span Olympic level training, building the next generation of Olympic champions, and transformation of teamwork across a Healthcare system with psychological safety.0:00 Timeline - Highlights2:12 - Intro: 3 Key Messages - Evidence-based Confidence, Clarity, and Psychological Safety3:28 - Biggest lesson on Confidence during the Toughest Season (2006)4:57 - Measure what Matters: Heart Rate, Stroke Rate, Time, Perceived Exertion5:35 - Challenge: Beat the Average from Previous Week5:51 - Turning Point: Started to be obsessed with Progress7:10 - Leadership Phase after Retirement7:27 - Ambition Programme - Team Great Britain - less than 8% of first time Olympians medal, intense build-up, media attention of the Olympics8:35 Pilot Project of First-time Olympians Created environment for potential stars to feel like Olympians, media mock-interviews, etc.9:41 Ambition Programme Alumni & Results307 athletes have finished this program40% represent Team GB 11% of the athletes in the program win a medal10:12- When we get clear we level up certainty Ask it, answer it, and action it - the last one drives certainty10:50 - Collaboration with the National Health Service in the UKNew programs: 1) Creating Psychological Safety to share, contribute, and debate; 2) Radical Candor. In less than 18 months, the pilot transformed one department, then started to spread12:34 - Teamwork thrives on Psychological Safety12:56 - Keynote SummaryConfidence is built from evidenceWhen we are unclear, things become uncertain - Challenge to the audience!True teamwork starts when we are safe to take risks

#656: What would you do if someone in authority told you to do something that felt wrong? Most of us like to think we'd speak up, push back, stand our ground. But research tells a very different story. In fact, when Yale researchers conducted a famous experiment in the 1960s, they found that 65% of people would administer what they believed to be deadly electric shocks to another human being... simply because someone in a lab coat told them to. Today's guest has spent over 15 years studying why humans comply with authority - even when every fiber of our being is screaming that we shouldn't. And when it comes to our money, this tendency to comply with authority figures - from financial advisors to real estate agents to car salespeople - can cost us dearly. Dr. Sunita Sah began her career as a physician in the UK's National Health Service. During one particularly exhausting period as a junior doctor, she agreed to meet with a financial advisor who had contacted her at work. That meeting sparked questions that would shape the rest of her career: Why did she feel pressured to trust this advisor, even after learning he had a conflict of interest? Today, she's a tenured professor at Cornell University, where her groundbreaking research on compliance and influence has been featured in The New York Times and Scientific American. She's advised government agencies, served on the National Commission on Forensic Science, and helps leaders understand the psychology behind why we say "yes" when we really want to say "no." Whether you're meeting with a financial advisor, negotiating the price of a home, or discussing rates with a contractor, understanding the psychology of compliance could save you thousands of dollars - and help you make better financial decisions. Today's conversation isn't just about psychology - it's about protecting your wealth by learning when and how to say "no." Resources Mentioned in the Episode: - Website: sunitasah.com - Newsletter: Defiant By Design | Dr. Sunita Sah | Substack - Connect with Dr. Sunita Sah - Follow Dr. Sah on Instagram About Dr. Sunita Sah Dr. Sunita Sah is a tenured professor at Cornell University specializing in organizational psychology. Her research focuses on how and why people comply with authority, even against their better judgment. A former physician in the UK's National Health Service, Dr. Sah brings a unique perspective to understanding human behavior and decision-making. Her work has been featured in leading publications including The New York Times and Scientific American, and she has served as a Commissioner on the National Commission on Forensic Science. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This is a free preview of a paid episode. To hear more, visit www.louiseperry.co.ukMy guest today is Dan Hitchens, senior editor at First Things Magazine. We spoke about assisted suicide: the second and third order consequences of legalisation, why low fertility welfare states are increasingly drawn to this apparent solution to their financial woes, and why Britain's National Health Service would prove to be a particularly dangerous p…

In this explainer episode, we've asked Dr Emily Perry, research engagement manager at Genomics England, to explain what the Genomics England Research Environment is. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. You can listen to the previous episodes mentioned in this podcast How has a groundbreaking genomic discovery impacted thousands worldwide? What is the National Genomic Research Library If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Florence: What is the Genomics England Research Environment? My name is Florence Cornish and I'm here with Emily Perry, Research Engagement Manager at Genomics England, to find out more. So Emily, before we dive into the Research Environment, let's set some context. Could you explain what Genomics England is aiming to do as an organisation? Emily: So, Genomics England provides genome sequencing in a healthcare setting for the National Health Service in England. As we sequence genomes for healthcare, the benefit is that we can also put that genomic and clinical data out for research in a controlled manner, and then that can also feed back into healthcare as well. So, it's really, this kind of cyclical process that Genomics England is responsible for. Florence: And so, what do we mean when we say Research Environment? Emily: So, the Research Environment is how our researchers can get access to that clinical and genomic data that we get through healthcare. So, it's a controlled environment, it's completely locked down, so it's kind of like a computer inside a computer. And in there, the researchers can access all of the data that we have and also a lot of tools for working with it in order to do their research. We refer to the data as the National Genomics Research Library, or the NGRL. The NGRL data is provided inside the Research Environment Florence:  So you mentioned the National Genomic Research Library. If any listeners want to learn more about this, you can check out our previous Genomics 101 podcast: What is the National Genomic Research Library? And so Emily, could you talk about what kind of data is stored in this library? Emily: So the library is made up of both genomic data and clinical data, which the researchers use alongside each other. The genomic data includes what we call alignments, which is where we match the reads from sequencing onto a reference sequence, and variants, which is where we identify where those alignments differ from the reference sequence, and this is what we are looking for in genomic research. The clinical data includes the data that was taken from our participants at recruitment, so details of the rare disease, the cancer, that they have, but also medical history data. So, we work with the NHS and we're able to get full medical history for our participants as well. This is all fully anonymised, so there's no names, there's no dates of birth, there's no NHS numbers. It's just these identifiers which are used only inside the Research Environment and have no link to the outside world. Florence: And so how is this clinical and genomic data secured? Emily: So, as I said there's no names, there's no NHS numbers, there's no dates of birth.  And we have very strict criteria for how people can use the data. So researchers, in order to get access to the Research Environment, they have to be a member of a registered institution, they have to submit a project proposal for what it is that they want to study with the data. There's also restrictions on how they can get the data out, so they do all their research inside, there's no way that they can do things like copy and paste stuff out or move files. The only way that they can get data out of the Research Environment is going through a process called Airlock, which is where they submit the files that they want to export to our committee, who then analyse it, check that it's in accordance with our rules and it protects our participants' safety and that only then would they allow them to export it. Florence: Who has access to the Research Environment? Emily: We have researchers working with the Research Environment all over the world. There's 2 kind of major groups. One of them is academia, so this will be researchers working in universities and academic institutions. The other side of it would is industry - so this will be biotech, startups, pharma companies, things like that. Florence: And finally, can you tell us about some of the discoveries that have been made using this data? Emily: There's lots of really cool things that have come out of the Research Environment.  A recent story that came out of the Research Environment was the ReNU syndrome, it was initially just one family that they identified this in, and they were able to extend this discovery across and identify huge numbers of individuals who had this same disorder because they had their genomes within the Research Environment. Florence: You can hear more about this research in our previous Behind the Genes podcast: How has a groundbreaking genomic discovery impacted thousands worldwide? So, we'll wrap up there. Thank you so much, Emily, for sharing more about what we mean by the Genomics England Research Environment. If you'd like to hear more explain episodes like this, you can find them on our website, at www.genomicsengland.co.uk or wherever you get your podcasts. Thank you for listening.  

Aneurin Bevan's commitment to social justice led to the creation of the National Health Service in 1948 – one of the most ambitious social reforms in British history. He was an MP who stuck to his principles in the face of serious opposition, but was not without criticism in both his professional and personal life. Speaking to Lauren Good, Nye Davies charts Bevan's journey from the coalfields of South Wales to the corridors of Westminster. The HistoryExtra podcast is produced by the team behind BBC History Magazine. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome to this week's episode of the PEBCAK Podcast!  We've got four amazing stories this week so sit back, relax, and keep being awesome!  Be sure to stick around for our Dad Joke of the Week. (DJOW) Follow us on Instagram @pebcakpodcast   Please share this podcast with someone you know!  It helps us grow the podcast and we really appreciate it!   2016: The Dawn of Modern Ransomware The debut of Petya and Russian-affiliated groups like CryptoWall, TeslaCrypt, and Locky. Attacks were largely indiscriminate, targeting anyone from Fortune 500 companies to "Grandma's laptop." Early mitigation tactics, like installing Russian language packs to avoid infection, highlighted the state-tolerated nature of these groups.   2017: Ransomware Goes Mainstream A pivotal year with the WannaCry attack (attributed to North Korea's Lazarus Group) and NotPetya (Russian-backed), causing billions in damages to companies in multiple verticals. The SAMSAM attacks hit U.S. cities like Baltimore and Atlanta, marking Iran's brief foray into ransomware. Ransomware became a household name, sparking executive-level discussions in boardrooms.   2020: The Rise of Ransomware-as-a-Service Groups like Ryuk, REvil, and Conti refined ransomware into a business model, outsourcing tasks like initial access and money laundering. Double extortion emerged, with attackers stealing data and threatening to leak it, even if backups were restored. Some groups introduced “terms of service,” avoiding hospitals and schools to dodge law enforcement scrutiny.   2021: Critical Infrastructure in the Crosshairs High-profile attacks on Colonial Pipeline, JBS Foods, and Ireland's National Health Service disrupted daily life, from gas shortages to meat supply issues. These incidents underscored ransomware's real-world impact, elevating cybersecurity to a boardroom priority.   2022: Geopolitical Shifts and New Players Russian-backed groups like Conti and LockBit shifted focus to Ukraine amid the Russia-Ukraine conflict. The rise of Scattered Spider, a Western-based group excelling at social engineering and SIM swapping, marked a shift from Eastern state-tolerated actors.   2023: Trust Breaks Down The ALFV/BlackCat group's $22 million rug pull against affiliates signaled the decline of Russian-backed ransomware dominance. Scattered Spider solidified its reputation, targeting major hospitality and cleaning companies with sophisticated social engineering tactics.   2025: The Western Cybercrime Surge Scattered Spider and affiliates like DragonForce dominate, hitting retailers, insurance, aviation, and automotive sectors. The shift to Western-based actors, often young and operating in Five Eyes nations, makes them more vulnerable to law enforcement.   Trends and Takeaways The move from expensive zero-day exploits to cheaper n-day exploits and social engineering highlights attackers' adaptability. Double extortion and even “double dipping” (demanding additional ransoms months later) have become standard tactics. The accessibility of AI tools and open-source platforms like Venice AI has lowered the barrier for creating ransomware, even for non-programmers. Law enforcement's increasing success in arrests and Bitcoin recovery (e.g., DarkSide's downfall) offers hope for curbing cybercrime.       Dad Joke of the Week (DJOW)   Find the hosts on LinkedIn: Chris - https://www.linkedin.com/in/chlouie/ Ben - https://www.linkedin.com/in/benjamincorll/

In this episode with Luke Murray we discuss Paul Ingraham's e-book on plantar fasciitis. We cover:Common causes of plantar fasciitisIs stretching effective for plantar fasciitis?Strengthening for the treatment of plantar fasciitisAnd more!

Roughly 1 in 10 Americans take antidepressants. The most common type is SSRIs, or  selective serotonin re-uptake inhibitors, like Prozac, Lexapro, and Zoloft. But what happens when you stop taking them? Studies don't point to a single conclusion, and there's ongoing debate among physicians and patients about the severity and significance of SSRI withdrawal symptoms. The discourse reached a fever pitch when Health Secretary Robert F. Kennedy Jr. compared SSRI withdrawal to heroin withdrawal in January.Host Flora Lichtman digs into the data on SSRI withdrawal with psychiatrists Awais Aftab and Mark Horowitz.Guests: Dr. Awais Aftab is a clinical associate professor of psychiatry at Case Western Reserve University.Dr. Mark Horowitz is a clinical research fellow in the UK's National Health Service and  scientific co-founder of Outro Health.Transcripts for each episode are available within 1-3 days at sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

This episode of Integrative Cancer Solutions Dr. Karlfeldt features an in-depth conversation with Sarah Marsh, a representative of Genesis Care in the UK, focusing on the integration of exercise medicine into cancer treatment. Sarah introduces Genesis Care's services, which include private chemotherapy, radiotherapy, and immunotherapy across 14 centers, and shares her personal connection to cancer through her husband's experience. She emphasizes the organization's commitment to a personalized approach, offering patients a 12-week exercise program designed to improve strength, manage side effects like fatigue and nausea, and enhance overall quality of life. The discussion explores the differences between private and public healthcare systems in the UK and Sweden, highlighting how Genesis Care collaborates with the National Health Service and runs clinical trials that benefit both sectors. Sarah explains that her five-year tenure at Genesis Care has given her insight into the unique needs of cancer patients, particularly the importance of meeting patients where they are and gradually reintroducing exercise routines that may have been disrupted by diagnosis and treatment. A significant portion of the conversation centers on the evidence supporting exercise as a critical component of cancer care. Sarah details how personalized exercise programs, including strength and balance training, can reduce the risk of cancer recurrence and help patients regain confidence and physical capability. She stresses the importance of flexibility and accessibility, encouraging patients to start with small steps and build up their activity levels as they feel able. Beyond exercise, the episode delves into the adjunctive therapies and wellbeing services offered by Genesis Care, such as acupuncture, reflexology, sleep assistance, and menopause support. These services are integrated into the overall treatment plan to address symptoms like hot flushes and fatigue, providing a holistic approach to patient care. Sarah shares that patients who complete the 12-week program often see significant improvements in both strength and quality of life. The conversation concludes with practical advice for cancer patients and their families. Sarah encourages patients to advocate for themselves, seek information, and involve loved ones in their care journey. Drawing from her husband's experience, she underscores the value of structured exercise and a supportive network, reminding listeners that it is never too late to start moving and that every small effort contributes to improved wellbeing and resilience during cancer treatment.Sarah Marshall from Genesis Care UK discusses the benefits of integrating exercise medicine into cancer treatment, emphasizing personalized 12-week programs for patients.Genesis Care offers private chemotherapy, radiotherapy, and immunotherapy services across 14 centers, collaborating with both public and private healthcare sectors.Exercise is shown to help manage side effects like fatigue and nausea, reduce the risk of cancer recurrence, and improve patients' strength and quality of life.Additional wellbeing services such as acupuncture, reflexology, and sleep assistance are provided to support holistic patient care.Sarah encourages cancer patients to advocate for themselves, start with manageable exercise routines, and seek support from professionals and loved ones.Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering Cancerhttps://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-100% Off Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancerhttps://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-100% Off Discount Code: CANCERPODCAST2----Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Story 1: The term “fascist” has become the go-to insult among politicians and political steamers as of late, but how many of them understand the definition behind it? Will breaks down what the true definition of fascism is and explains how its misuse can potentially embolden some to commit acts of violence. Story 2: Congressman Andy Barr (R-KY) joins Will to discuss the rise in support for socialism in Democrats across the country, and the ripple effect it has had amongst the Democratic Party's politics. Plus, Rep. Barr and Will react to a viral clip of Kentucky legend Colonel Sanders' great-great-great nephew denouncing KFC's risqué marketing, before proceeding to reveal what he claims are the secret 11 herbs and spices. Story 3: Host of ‘The Rubin Report,' Dave Rubin helps Will break down the bizarre support from the UK's National Health Service for first cousin marriage, which they now claim leads to stronger social support systems and economic advantages? Will and Dave examine how such a study could have been published despite overwhelming evidence suggesting that such marriages lead to birth defects, and what a sudden influx of Pakistani migrants has to do with it. Plus, in Final Takes, Will and The Crew share their thoughts on last night's tie between the Cowboys & the Packers, before discussing Bad Bunny being selected to headline the Super Bowl halftime show.     Subscribe to ‘Will Cain Country' on YouTube here: ⁠⁠Watch Will Cain Country! ⁠⁠Follow ‘Will Cain Country' on X (@willcainshow), Instagram (@willcainshow), TikTok (@willcainshow), and Facebook (@willcainnews) Follow Will on X: ⁠⁠@WillCain  Learn more about your ad choices. Visit podcastchoices.com/adchoices

At this year's Evidence Based Perioperative Medicine (EBPOM) World Congress we sat down with Ramani Moonesinghe OBE, and had a conversation about her remarkable journey from her immigrant roots to her influential roles in perioperative and critical care. Hear about her contributions to Britain's National Health Service, her groundbreaking research, and her personal life balancing a demanding career with family. Gain insights into the future of perioperative care, health inequalities, and her thoughts on the nation's COVID-19 preparedness. Presented by Andy Cumpstey with Ramani Moonesinghe OBE, Professor of Perioperative Medicine, UCL, and Honorary Consultant in Anaesthesia and Perioperative Medicine, UCLH, London, UK.

Dr. Sarah Myhill has worked full time in National Health Service and independent medical practice. She has a special interest in Chronic Fatigue Syndrome and ME. Show partners: Troscriptions - 10% off your first order by using the code "JESSE" at checkout Quicksilver Scientific - 15% off your first order by using the code "jesse15" at checkout Maui Nui Venison - Get yourself some high quality venison using this link Show notes: https://jessechappus.com/670

In part six of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Krissy Dilger of SRNA was joined by Barbara Babcock, a family therapist from the UK's National Health Service, to discuss the role of siblings in families with a child diagnosed with a rare neuroimmune disorder. Barbara shared findings from her research on how siblings provide crucial support to parents and the positive impacts this has on family dynamics [00:04:31]. They explored the concept of parentification and the importance of assigning age-appropriate tasks to siblings [00:25:10]. Barbara also provided advice on fostering healthy sibling relationships and the significance of open communication [00:35:34]. At the end of this mini-series, we will host a Q&A episode where Barbara will answer questions from the community. To submit your question, please visit https://srna.ngo/submitBarbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdom's National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk00:00 Introduction00:28 Meet Barbara Babcock02:08 Theme Four: Support from Siblings04:31 Siblings' Characteristics and Their Impact06:57 Voluntary Help from Siblings25:10 Parentification: Understanding the Concept36:34 Fostering Healthy Sibling Relationships39:20 Conclusion and Final Thoughts

In this episode, we dive into how artificial intelligence is being developed, tested, and trusted within the UK's National Health Service. Our guest is Adam Byfield, a principal technical assurance specialist with a unique journey from astrophysics to AI assurance. Adam leads a team adapting traditional software testing methods to ensure AI tools in healthcare are safe, effective, and fair,augmenting, not replacing, clinicians. Stay tuned as we unpack the challenges, breakthroughs, and the future of AI in the NHS.

Security professionals have to be integrated into operational resilience efforts and business continuity planning to prevent disruptions of all kinds, according to new research from the ASIS Foundation. In this episode of the SM Highlights podcast, report co-author and ResOrgs principal consultant Joanne Stevenson shares why security gets left out of resilience discussions and what they can do about it. Then, Don Aviv, CPP, PCI, PSP, CEO of Interfor International, discusses what happened during a shooting at a Manhattan office building in July and how proactive threat monitoring can change the nature of site security. Additional Resources Read the ASIS Foundation research, Operational Resilience: The Critical Contribution of Security to Operational Resilience, online here: https://store.asisonline.org/asis-foundation-operational-resilience.html?_gl=1*1l3liqy*_gcl_au*MTE5NTA5MjQzMC4xNzUxMzk3MDA3*_ga*NzQxNzQ1OTA0LjE3NTEzOTcwMDg.*_ga_0ZPVSP549B*czE3NTY4MTYwMjAkbzIwMiRnMSR0MTc1NjgxNjcxNCRqNjAkbDAkaDA ASIS members can access the report for free. Read the free executive summary here: https://www.asisonline.org/globalassets/foundation/research/asis-foundation-operational-resilience-executive-summary.pdf For an overview and analysis of some of the key points of the research, read Security Management's take here: https://www.asisonline.org/security-management-magazine/latest-news/today-in-security/2025/july/Security-Operational-Resilience-Planning/ For more on the cyberattack on the National Health Service in 2017, read the National Audit Office's investigation report: https://www.nao.org.uk/reports/investigation-wannacry-cyber-attack-and-the-nhs/ Interested in using human-centric narratives to back up your metrics? Get some advice and examples here: https://www.asisonline.org/security-management-magazine/articles/2025/03/metrics/crafting-metrics-story/ Interested in how to build out a resilience function, including a crisis response team? Read this article from the SM archive: https://www.asisonline.org/security-management-magazine/articles/2024/07/resilience/create-crisis-managment-team/ Get an overview of the shooting at 345 Park Avenue in Manhattan in Security Management's coverage here: https://www.asisonline.org/security-management-magazine/latest-news/today-in-security/2025/july/345-park-ave-shooting/ Research past security incidents in high-rise buildings here: https://www.asisonline.org/security-management-magazine/articles/2021/03/mitigating-rising-risks-for-high-rises/ Learn more about digital threat monitoring and assessment on social media here: https://www.asisonline.org/security-management-magazine/articles/2025/08/threat-assessment/ Want to explore the changing nature of risk further with Don Aviv, CPP, PCI, PSP, and other security experts? Attend the Game Changer sessions at GSX: https://www.gsx.org/game-changers/

As natural thyroid ban looms, thyroid sufferers gird for battle with regulators; Rapid weight loss, muscle wasting—what to do? Could overuse of CT scans cause 100,000 extra cancers in the U.S.? Martha's Vineyard, Nantucket residents afflicted with tick-borne meat allergy; Beyond Meat headed for Chapter 11 bankruptcy; Searching for the causes of low iron.

With all the fun of EdFringe now in full swing, what better way to celebrate the world's biggest arts festival than with another delicious slice of conversation between Thos and Zach Burns, the multitalented perfomer, writer, actor, musician and Fringe veteran! In this fantastic episode, they discuss the eponymously named Fringe! The Musical, the nature of formal musical theatre training, and Zach's latest project, a brand new musical about the birth of the National Health Service called "For All Time".  All this and an exclusive recording of the title song, you'd be potty to miss it.  All together now:  "Tuesday?!"  

At the end of this mini-series, we will host a Q&A episode where Barbara will answer questions from the community. To submit your question, please visit https://srna.ngo/submitIn part five of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Krissy Dilger of SRNA was joined by Barbara Babcock to further explore her research concerning the changing beliefs around parenting when a child has been diagnosed with a rare neuroimmune disorder. They explored the theme of finding a balance in attending to the needs of all children in the family and discussed the importance of fairness and communication between parents [00:02:18]. The conversation also touched on the cultural differences and how these influence family dynamics and parenting strategies when one child requires more attention [00:13:33]. Barbara shared various strategies families use to ensure each child feels valued, such as integrating quality time into existing routines and understanding the different needs of children at various developmental stages [00:18:30]. Barbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdom's National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk00:00 Introduction 00:28 Meet the Expert: Barbara Babcock02:18 Theme Three: Balancing Sibling Needs03:59 Parental Communication and Mutual Support13:33 Cultural and Family Contexts18:30 Building Quality Time with Siblings26:13 Parental Guilt and Compensation35:09 Conclusion

At the end of this mini-series, we will host a Q&A episode where Barbara will answer questions from the community. To submit your question, please visit https://srna.ngo/submitIn the fourth part of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Krissy Dilger of SRNA continued her conversation with Barbara Babcock. In this episode, Barbara, a family therapist, discussed her research of parental fatigue and limited time distribution among families of children who have been diagnosed with a rare neuroimmune disorder. She elaborated on the non-stop nature of caregiving roles and the impact of work and daily parenting responsibilities on parental exhaustion [00:05:10]. Barbara emphasized the importance of parents finding ways to cope, from getting social support to attending to their own basic needs [00:17:35]. She highlighted the significance of confidence in navigating the complexities of family life and caregiving for a child with special needs [00:21:27].00:00 Introduction01:29 Theme Two: "I Can Only Split Myself So Many Ways"05:10 Parental Exhaustion and Coping Mechanisms17:35 Balancing Social and Extracurricular Activities21:27 Building Confidence as a Family23:28 ConclusionBarbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdom's National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk

At the end of this mini-series, we will host a Q&A episode where Barbara will answer questions from the community. To submit your question, please visit https://srna.ngo/submitIn the third part of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Krissy Dilger of SRNA was joined by Barbara Babcock to further explore her research concerning the changing beliefs around parenting when a child has been diagnosed with a rare neuroimmune disorder. Barbara discussed how beliefs around being fair as a parent could change and the various sub-themes supporting this idea, including redefinition of fairness and the challenge of balancing attention among children [00:03:30]. She highlighted the impact of societal and historical contexts on parenting norms and the struggles parents face in managing new caregiving responsibilities and learning new skills [00:12:45]. The importance of redefining what it means to be a good parent in the context of a child with additional needs was emphasized throughout the episode [00:24:00]. Barbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdom's National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk00:00 Introduction 00:27 Meet the Expert: Barbara Babcock01:38 Exploring Parental Beliefs and Fairness03:37 Balancing Attention Among Children07:49 Cultural and Societal Influences on Parenting11:08 Challenges in Managing Illness and Fairness19:37 Learning New Skills and Roles25:52 Redefining Good Parenting27:43 Conclusion

The number of people 85 years and older is expected to double in the U.K. over the next couple of decades. Apian, a London-based health care logistics company that partners with the National Health Service, thinks automation can help. We visit Apian to understand how automated robots could ease the burden of caring for an aging population. Also in this episode: A pilot pushes for menopause policies at British Airways, and an entrepreneur launches a skincare business at 50.Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.Marketplace is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.

The number of people 85 years and older is expected to double in the U.K. over the next couple of decades. Apian, a London-based health care logistics company that partners with the National Health Service, thinks automation can help. We visit Apian to understand how automated robots could ease the burden of caring for an aging population. Also in this episode: A pilot pushes for menopause policies at British Airways, and an entrepreneur launches a skincare business at 50.Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.Marketplace is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.

Donald Trump has secured passage of his flagship tax and spending legislation and the US jobs market exceeded expectations last month. Plus, the future of the UK's National Health Service could be in jeopardy, and Hong Kong residents cancel trips to Japan over a comic book's earthquake prophecy. Mentioned in this podcast:What is in Donald Trump's giant tax-cutting billUS economy surpasses expectations to add 147,000 jobs in JuneThe future of the NHS 10-year plan NHSHongkongers scrap Japan trips over comic book's earthquake prophecyToday's FT News Briefing was produced by Sonja Hutson and Katya Kumkova. Additional help from Blake Maples, Michael Lello, and Gavin Kallmann. Our acting co-head of audio is Topher Forhecz. Our intern is Michaela Seah. The show's theme song is by Metaphor Music.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Send us a textSeason 2 Episode 50The Boy's are back in town (no guest this week), Martin gives us a full update on his recent visit to see his Oncologists "Dr P" for an update on his health, Cancer and the results of his most recent Cancer Scan.The results didn't go the way things had been planned and Martin receives the news that a visit to the "Royal Marsdon Hospital" in Chelsea London is required. The Royal Marsden Hospital is a specialist National Health Service oncology hospital in London based at two sites in Brompton, in Kensington and Chelsea, and Belmont in Sutton. It is managed by The Royal Marsden NHS Foundation Trust and supported by The Royal Marsden Cancer Charity.Listen to Martin as he tells us about his news and the next steps in his treatment to carry on the battle of his Stage 4 Cancer.We do finish on a light note today with "Martins Joke of the week"https://www.royalmarsden.nhs.uk#HeartTransplant#eatingdisorder#RareCondition#HealthJourney#LifeChangingDiagnosis#MentalHealth#Vulnerability#SelfCompassion#PostTraumaticGrowth#MedicalMiracle#BBCSports#Inspiration#Cardiology#Surgery#Podcast#Healthcare#HeartHealth#MedicalBreakthrough#EmotionalJourney#SupportSystem#HealthcareHeroes#PatientStories#CardiologyCare#MedicalJourney#LifeLessons#MentalWellness#HealthAwareness#InspirationalTalk#LivingWithIllness#RareDiseaseAwareness#SharingIsCaring#MedicalSupport#BBCReporter#HeartDisease#PodcastInterview#HealthTalk#Empowerment#Wellbeing#HealthPodcast#Harryhill#Aid's#HIVCheck out our website at www.whostomanddick.com

At the end of this mini-series, we will host a Q&A episode where Barbara will answer questions from the community. To submit your question, please visithttps://srna.ngo/submitIn the second part of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Barbara Babcock shared more about her research on how parents navigate the needs of their non-diagnosed children alongside those of a child with a rare neuroimmune disorder. She described the demographic details of the participating families and the process of recruiting participants for the study [00:02:25]. Barbara highlighted her unique perspective and the potential biases she brought to the research as a non-parent [00:05:33]. She emphasized the importance of honesty and vulnerability in sharing experiences, as well as focusing on the strengths of families facing these challenges [00:09:46]. Barbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdom's National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk00:00 Introduction01:29 Overview of Barbara's Research02:25 Participant Demographics and Methodology05:33 Researcher's Perspective and Bias09:46 Themes and Insights from the Research12:24 Conclusion

Addressing Fatigue: The Role of Nutrient Deficiencies and Lifestyle Changes. Nutritionist Leyla Muedin details the various causes and potential solutions for fatigue. She highlights how nutrient deficiencies, particularly in vitamins B12, D, and minerals like iron and magnesium, contribute to tiredness. Leyla emphasizes the importance of understanding the root cause of symptoms in integrative and functional medicine. She also touches on lifestyle factors such as stress, sleep patterns, high carbohydrate diets, and alcohol consumption that may exacerbate fatigue. Practical advice on dietary changes and the significance of regular check-ups for vitamin levels is provided, aiming to help listeners address fatigue and improve overall wellness naturally.

At the end of this mini-series, we will host a Q&A episode where Barbara Babcock will answer questions from the community. To submit your question, please visit:https://srna.ngo/submitIn the first part of the “Ask the Expert, Research Edition” mini-series, “Parenting is Hard,” Barbara Babcock discussed the challenges faced by parents raising a child with a rare neuroimmune disorder and the impact on non-diagnosed siblings. Barbara shared her personal journey with transverse myelitis (TM) and how it led her to conduct research on this topic [00:02:20]. She explored themes from her research, highlighting fairness in parenting, and the role of sibling support [00:13:03]. Finally, Barbara emphasized the importance of adapting parenting strategies to balance the needs of all children in the family [00:15:42]. Barbara Babcock works as a Family Therapist in a child and adolescent mental health outpatient unit in the United Kingdom's National Health Service. In her private practice, she works with individuals and couples who are navigating challenging health issues and wish to get their lives back. She obtained her Master of Science in Family Therapy from the Institute of Psychiatry, Psychology, and Neuroscience at King's College London. Barbara also has a Master of Arts in Coaching Psychology/Psychological Coaching and her dissertation research focused on the impact that a systemic approach to coaching has on the wellbeing of adults who have a rare neuroimmune disorder and their primary caregivers. Previously, she was Chair of the Transverse Myelitis Society, from 2013 to 2016, and led their Family Weekend from 2015 to 2019, an event to support families who have a child/adolescent with a rare neuroimmune disorder to discover their potential through challenging outdoor activities. She had transverse myelitis in 2008 and is originally from Pennsylvania, USA. You can contact her at barbara@returntowellness.co.uk and her website is www.returntowellness.co.uk00:00 Introduction01:26 Meet Barbara Babcock: A Journey into Family Therapy02:20 Barbara's Personal Experience with TM03:20 Creating Support Systems for Families06:35 Research Focus: Parenting and Sibling Dynamics13:03 Themes from the Research15:42 The Importance of Fairness and Balance18:38 Challenges and Guilt in Parenting24:33 Conclusion

Dr. Sarah Myhill has worked full time in National Health Service and independent medical practice. She has a special interest in Chronic Fatigue Syndrome and ME. Show sponsors: Quicksilver Scientific - 15% off your first order by using the code "ultimatehealth15" at checkout Troscriptions - 10% off your first order by using the code "JESSE" at checkout Show notes: https://jessechappus.com/657

It's Friday, May 16th, A.D. 2025. This is The Worldview in 5 Minutes heard on 125 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Adam McManus Nigerian Muslims kill 2 Christian teachers Boko Haram Muslim terrorists recently targeted Christians traveling near a Nigerian army base along the deadly Damboa–Maiduguri highway, reports International Christian Concern. On May 12th, two Christian teachers were killed and several others were injured when their vehicle struck an improvised explosive device allegedly planted by the Islamic terror group. Blessing Luka and Gideon Bitterleaf were both devoted Christian educators with the Damboa Local Education Authority. Pray that these Muslim murderers will be held accountable. Genesis 9:6 says, "Whoever sheds human blood, by humans shall their blood be shed; for in the image of God has God made mankind." More children in United Kingdom have gender dysphoria Soaring numbers of children in England and Wales are waiting for specialist gender care from the National Health Service -- as youngsters of any age are now eligible for referral after the health service “caved to the pressure” of transgender activists to remove age limits, reports The Daily Mail and World Magazine. Average waiting times have grown to more than two years for a confused child to get a first appointment at a specialist health service clinic, with 157 of those aged under ten. There were 6,225 confused kids on the national waiting list at the end of March. That's up 12 per cent from the same point a year earlier. Young children believed to have gender dysphoria are generally given counselling and therapy with their family, but thankfully no longer prescribed hormone treatments.  Indeed, Britain's National Health Service has moved away from a “medical model” in favor of a “holistic” approach to children's gender care, as per recommendations from the Cass Review. Puberty blockers are no longer prescribed to children for the treatment of gender dysphoria, after a ban last year was made permanent in December. Former FBI Director calls for Trump's assassination Former FBI Director James Comey is facing massive backlash after he posted a photo on his Instagram page calling for the assassination of President Donald Trump, reports Christian Talk show host Todd Starnes. An image of seashells that had been arranged on the beach to spell “86 47” was posted on Comey's personal Instagram account. The number “86” is code for killing someone. And, of course, “47” refers to the fact that Donald Trump is the 47th president of the United States. Comey wrote, “Cool shell formation on my beach walk.” Homeland Security Secretary Kristi Noem tweeted, “Disgraced former FBI Director James Comey just called for the assassination of President Trump. [the Department of Homeland Security] and Secret Service is investigating this threat and will respond appropriately.” And Republican Senator Tommy Tuberville of Alabama tweeted, “This is a direct THREAT against President Trump, who has already survived two assassination attempts. BEYOND despicable. James Comey MUST face consequences.” RFK Jr. agrees to examine the dangers of Abortion Kill Pill A recent study by the Ethics and Public Policy Center on the Abortion Kill Pill, mifepristone, showed that 11% of women experience adverse effects serious enough to send them to the Emergency Room. That's 22 times higher than what the Food and Drug Administration claims.   Appearing before the Senate Health, Education, Labor, and Pensions Committee on May 15th, Health and Human Services Secretary Robert F. Kennedy Jr. agreed to a comprehensive review and relabeling of Mifepristone in response to a pointed question from Republican Senator Josh Hawley of Missouri, reports The Guardian. Listen. HAWLEY: “There's been a major study by the Ethics and Public Policy Center of 865,727 prescribed cases of mifepristone abortions, chemical abortions, between 2017 and 2023. This data shows the biggest study on mifepristone done, I think, ever, and it showed that nearly 11% of women experience very serious adverse health effects to include sepsis, hemorrhaging, infection, of course, emergency room visits. That rate is 22 times higher than the FDA's current label which says it's just 0.5 the incidence of serious adverse health events. “So, my question to you is this: You previously testified at the committee that you would do a top-to-bottom review of mifepristone. Do you continue to stand by that? And don't you think that this new data shows the need to do a review is, in fact, very pressing?” KENNEDY: “It's alarming, and clearly it indicates that, at very least, the label should be changed. I've asked Marty Makary, who's the director of FDA, to do a complete review and to report back.” HAWLEY: “Good!” South Carolina Supreme Court affirms Heartbeat Law The South Carolina Supreme Court ruled that the state may enforce its heartbeat-based abortion ban, rejecting an argument by Planned Parenthood to weaken the law, reports LifeSiteNews.com. Enacted in 2023, the law effectively bans most abortions after about six weeks gestation. South Carolina Republican Governor Henry McMaster told the Daily Wire, “Time and time again, we have defended the right to life in South Carolina, and time and time again, we have prevailed. Today's ruling is another clear and decisive victory that will ensure the lives of countless unborn children remain protected and that South Carolina continues to lead the charge in defending the sanctity of life.” Psalm 127:3 says, "Children are a heritage from the Lord, the fruit of the womb a reward." Christian band under fire by atheists and superintendent And finally, a popular Christian band is under fire from atheists along with Davidson County Schools in North Carolina, reports Blue Ridge Broadcasting. The 3 Heath Brothers band had been invited to host an anti-bullying event at Hasty Elementary School. Their performance included a number of songs that mentioned God. Afterwards, they gave the kids a devotional pamphlet that included Bible verses. The Freedom From Religion Foundation was enraged over the performance and accused the school of being a recruiting ground for Christianity. The God-hating attorney, Madeline Ziegler, wrote, “The district cannot allow non-school persons to treat schools as a recruiting ground for their religious mission.  Public schools are not an appropriate place for outside adults to convince students to convert to Christianity.” Sadly, the School Superintendent Gregg Slate was just as horrified with the Christian band and wrote a lengthy letter of apology to the atheists. But then, the school district went a step further. They had the audacity to demand that the 3 Heath Brothers remove video of the event from their social media pages. A bizarre request indeed. School officials claim they were duped. But Nicholas Heath of the 3 Heath Brothers denied that there was any proselytizing or worship service at the event. Close And that's The Worldview on this Friday, May 16th, in the year of our Lord 2025. Subscribe for free by Spotify, Amazon Music or by iTunes or email to our unique Christian newscast at www.TheWorldview.com. Or get the Generations app through Google Play or The App Store. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

Dr. Nadeem Haddadin-Crowe discusses witch hunts in the National Health Service prompted by politicians and Israel lobby groups.